AMPK activator (CBDA) and sglt2 inhibitors for metabolic health
By combining AMP-activated protein kinase activators with SGLT2 inhibitors, AMPK is synergistically activated, solving the problem of poor efficacy of AMPK activators in existing technologies and achieving better metabolic health improvement.
Patent Information
- Application Number
- CN202380033794.9
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-05-04
- Filing Date
- 2023-04-28
- Publication Date
- 2024-11-22
AI Technical Summary
There is a lack of effective AMPK activators in the current technology, and existing AMPK activators have low oral bioavailability or adverse effects such as increased cardiac glycogen content and hypertrophy. SGLT2 inhibitors alone have also failed to adequately improve metabolic health. Therefore, a synergistic combination is needed to activate AMPK to improve metabolic health.
By combining AMP-activated protein kinase activators (such as CBDA, CBGA, or CBNA) with sodium-glucose cotransporter-2 (SGLT2) inhibitors, AMPK is synergistically activated to improve metabolic health.
Compared with the use of AMPK activators or SGLT2 inhibitors alone, this composition significantly improves AMPK activation and glucose clearance, synergistically enhancing metabolic health.
Smart Images

Figure BDA0005080424090000041 
Figure BDA0005080424090000051 
Figure BDA0005080424090000052
Abstract
Description
Background Art
[0001] The present disclosure generally relates to compositions and methods for improving metabolic health. Specifically, the present disclosure relates to a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, or CBNA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor for improving metabolic health. For example, a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, or CBNA) and a SGLT2 inhibitor for synergistically activating AMPK and improving metabolic health.
[0002] AMP-activated protein kinase (AMPK) is an evolutionarily conserved master regulator of energy homeostasis that coordinates metabolic pathways to balance nutrient supply with energy demand. AMPK is considered a key drug target to combat increasingly prevalent metabolic disorders such as obesity, type 2 diabetes, and cardiovascular disease.
[0003] AMPK activity is present in all tissues, including liver, kidney, muscle, lung and brain (PMID: 10698692). Structurally, AMPK is a heterotrimeric complex consisting of a catalytic subunit (α) and two regulatory subunits (β and γ). The AMPK complex is evolutionarily conserved and can also be found in yeast and plants. Mammalian AMPK consists of subunits of different isotypes: αα1, α2, β1, β2, γ1, γ2 and γ3 (PMID: 11746230), resulting in 12 possible heterotrimeric combinations. The α2 isoform is mainly found in skeletal muscle and cardiac muscle AMPK; both α1 and α2 isoforms are found in liver AMPK; and, for example, in adipocytes and T cells, the α1 isoform AMPK is dominant (PMID: 16818670, PMID 15878856).
[0004] Despite the continued efforts of the pharmaceutical industry, there are no direct AMPK activating drugs available for the treatment of metabolic disorders. Several synthetic AMPK activators have been identified / developed. However, they either have no oral availability / poor oral availability (PMID: 16753576, PMID: 24900234) or there are concerns about their adverse effects off-target, as chronic and strong AMPK activation may lead to increased cardiac glycogen content and hypertrophy (PMID: 11827995).
[0005] Finding natural bioactive molecules that modestly activate AMPK with a defined mechanism of action, especially in muscle, liver, and kidney, may provide exercise-mimicking effects and help maintain / improve metabolic health.
[0006] There are many natural compounds / extracts known to confer some metabolic health benefits, suggesting that these benefits are most likely to indirectly stimulate AMPK by inhibiting mitochondrial respiration. However, whether these metabolic effects are mediated by AMPK is largely elusive, and there are also concerns about side effects / toxic effects (such as cell or mitochondrial poisoning).
[0007] Sodium-glucose cotransporter-2 (SGLT2) inhibitors are a class of insulin-independent, oral antihyperglycemic drugs used by clinicians to treat type 2 diabetes. Since 2013, the Food and Drug Administration has approved four SGLT2 inhibitors: canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin.
[0008] SGLT2 inhibitors are a class of prescription drugs that are FDA-approved for use with diet and exercise to lower blood sugar in adults with type 2 diabetes. Drugs in the SGLT2 inhibitor class include canagliflozin, dapagliflozin, and empagliflozin. They are available as single ingredient products and also in combination with other diabetes drugs such as metformin. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through the urine.
[0009] There is a clear unmet need for novel compositions, combinations of AMP-activated protein kinase (AMPK) activators (e.g., CBDA, CBGA, or CBNA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors for improving metabolic health. What is needed in the art is a combination of AMP-activated protein kinase (AMPK) activators (e.g., CBDA, CBGA, or CBNA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors for synergistically activating AMPK, thereby improving metabolic health. Summary of the invention
[0010] The present disclosure includes the recognition that administering to a subject a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, or CBNA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor for co-activating AMPK would represent a breakthrough in improving metabolic health. In fact, the method of administering to a subject a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, or CBNA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor disclosed herein results in improved performance of activated AMPK compared to administering an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, or CBNA) or a sodium-glucose cotransporter-2 (SGLT2) inhibitor alone. BRIEF DESCRIPTION OF THE DRAWINGS
[0011] Figure 1 Figure 1A and Figure 1B ) is a set of graphs showing glucose clearance in zebrafish according to certain embodiments of the present invention. Figure 1A It was shown that the combination of CBD and Dapa improved glucose clearance in zebrafish compared to CBD and Dapa (SGLT-2 inhibitor) alone. Figure 1B It was shown that the combination of CBDA and Dapa improved glucose clearance in zebrafish compared to CBDA and Dapa (SGLT-2 inhibitor) alone. DETAILED DESCRIPTION
[0012] definition
[0013] Some definitions are provided below. However, definitions may be located in the "embodiment" section below, and the above heading "definitions" does not indicate that such disclosure in the "embodiment" section is not a definition.
[0014] All percentages expressed herein are by weight based on the total weight of the composition, unless otherwise indicated. As used herein, "about", "approximately" and "substantially" should be understood to refer to numbers within a certain numerical range, such as within the range of -10% to +10% of the mentioned number, preferably -5% to +5% of the mentioned number, more preferably -1% to +1% of the mentioned number, and most preferably -0.1% to +0.1% of the mentioned number. All numerical ranges herein should be understood to include all integers or fractions within the range. In addition, these numerical ranges should be understood to provide support for claims involving any number or subset of numbers within the range. For example, the disclosure of 1 to 10 should be understood to support ranges of 1 to 8, 3 to 7, 1 to 9, 3.6 to 4.6, 3.5 to 9.9, etc.
[0015] As used in this disclosure and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Thus, for example, reference to "a component" or "the component" includes two or more components.
[0016] The words "comprising" will all be interpreted as inclusive rather than exclusive. Likewise, the terms "including" and "or" will all be considered inclusive unless the context clearly prohibits such an interpretation. However, the compositions disclosed herein may be free of any elements not specifically disclosed herein. Thus, disclosures of embodiments using the term "comprising" include disclosures of embodiments "consisting essentially of the specified components" and embodiments "consisting of the specified components."
[0017] The term "and / or" used in the context of "X and / or Y" should be interpreted as "X" or "Y" or "X and Y". Similarly, "at least one of X or Y" should be interpreted as "X" or "Y" or "X and Y". For example, "at least one dithionite or a functionally similar reducing agent" should be interpreted as "dithionite" or "functionally similar reducing agent" or "both dithionite and a functionally similar reducing agent".
[0018] As used herein, the terms "example" and "such as" (especially when followed by a list of terms) are exemplary and illustrative only and should not be considered exclusive or comprehensive. As used herein, one condition is "associated with" or "associated with" another condition means that the conditions occur at the same time, preferably means that the conditions are caused by the same underlying condition, and most preferably means that one of the identified conditions is caused by the other identified condition.
[0019] As used herein, the term "cannabidiol acid" or "CBDA" refers to 2,4-dihydroxy-3-[(1R, 6R)-3-methyl-6-prop-1-en-2-ylcyclohex-2-en-1-yl]-6-pentylbenzoic acid, CAS No. 1244-58-2. It is also known as 2,4-dihydroxy-3-[(1R, 6R)-3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl]-6-pentyl-benzoic acid, (1R-trans)-2,4-dihydroxy-3-[3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl]-6-pentyl-benzoic acid, 3-p-menthth-1,8-diene-3-yl-6-pentyl-β-resorcinol, cannabidiol carboxylic acid or cannabinoid CBDA. It has the following formula:
[0020]
[0021] As used herein, the term "retsoric acid" refers to a type of dihydroxybenzoic acid. In one embodiment, retsoric acid can include any of 3,5-dihydroxybenzoic acid (α-retsoric acid), 2,4-dihydroxybenzoic acid (β-retsoric acid) or 2,6-dihydroxybenzoic acid (γ-retsoric acid) or their derivatives.
[0022] As used herein, the term "cannabidiol" or "CBD" refers to 2-[(1R, 6R)-6-isopropenyl-3-methylcyclohex-2-ene-1-yl]-5-pentylbenzene-1,3-diol. It is also known as 2-[(1R, 6R)-3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene, trans-(-)-2-p-menthyl-1,8-diene-3-yl-5-pentyl-resorcinol, (1R-trans)-2-[3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl]-5-pentyl-1,3-benzene, Epidiolex, GWP 42003P or Epidyolex. It has the following formula:
[0023]
[0024] As used herein, the term "cannabigerolic acid" or "CBGA" refers to the acidic form of cannabigerol (CBG). It is a dihydroxybenzoic acid and an oleotriol acid in which the hydrogen at position 3 is replaced by a geranyl group. It is a biosynthetic precursor of delta-9-tetrahydrocannabinol, which is the main psychoactive ingredient of the cannabis plant. It is also a member of the diterpenes, polyketides, resorcinols, and phytocannabinoids. It is derived from oleotriol acid. It is the conjugate acid of cannabigerol ester. It has the following formula:
[0025]
[0026] As used herein, the term "cannabinolic acid" or "CBNA" refers to 1-hydroxy-6,6,9-trimethyl-3-pentyl-6H-benzo[c]chromene-2-carboxylic acid. It is also known as 1-hydroxy-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-2-carboxylic acid, 1-hydroxy-6,6,9-trimethyl-3-pentylbenzo[c]chromene-2-carboxylic acid or 1-hydroxy-6,6,9-trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-2-carboxylic acid. It has the following formula:
[0027]
[0028] In one embodiment, the first compound of the present invention includes CBNA or a derivative or analog thereof. WO2021 / 105075 discloses examples of CBNA derivatives or analogs.
[0029] As used herein, the term "5'-adenosine monophosphate-activated protein kinase", "AMP-activated protein kinase" or "AMPK" refers to a heterotrimeric kinase composed of an alpha catalytic subunit and non-catalytic beta and gamma subunits. AMPK is an important energy sensing enzyme that monitors cellular energy status. In response to cellular metabolic stress, AMPK is activated and phosphorylates and inactivates acetyl-CoA carboxylase (ACC) and beta-hydroxy beta-methylglutaryl-CoA reductase (HMGCR), which are key enzymes involved in regulating the de novo biosynthesis of fatty acids and cholesterol, as well as other proteins involved in metabolism. AMPK and its role as an energy sensor have been reviewed in various publications, including: Kemp et al. (Trends Biochem. Sci. 1999 24:22-5), Hardie et al. (Bioessays. 2001 23:1112-9), Musi et al. (Curr. Drug Targets Immune Endocr. Metabol. Disord. 2002 2:119-27), Musi et al. (Biochem. Soc. Trans. 2003 31:191-5) and Hardie (Endocrinology. 2003 144:5179-83) and Aschenbach (Sports Med. 2004 34:91-103), which are incorporated by reference.
[0030] AMPK is a central regulator of energy homeostasis, coordinating metabolic pathways and thus balancing nutrient supply with energy demand. Due to the favorable physiological consequences of AMPK activation on metabolism, AMPK has been considered to be an important therapeutic target for controlling human diseases including metabolic syndrome and cancer. As a cellular energy sensor, AMP-activated protein kinase (AMPK) is activated in response to a variety of conditions that deplete cellular energy levels, such as nutrient starvation (especially glucose), hypoxia, and exposure to toxins that inhibit mitochondrial respiratory chain complexes. AMPK is a serine / threonine protein kinase complex composed of catalytic α-subunits (α1 and α2), scaffold β-subunits (β1 and β2), and regulatory γ-subunits (γ1, γ2, and γ3).
[0031] As used herein, the term "AMPK activation" refers to the phosphorylation state of AMPK or its direct targets. AMPK can be activated by regulating proteins upstream of AMPK (e.g., adiponectin receptor, leptin receptor, α-adrenergic receptor, or insulin receptor, etc.) or by AMPK itself. AMPK activation can be determined by measuring AMPK itself or downstream targets of AMPK.
[0032] As used herein, the term "AMP-activated protein kinase activator" or "AMPK activator" refers to any compound or substance that activates AMP-activated protein kinase (AMPK). For example, the EP application entitled "SUBSTITUTED RESORCYLIC ACID COMPOUNDSAS AMPKACTIVATOR, COMPOSITIONS, METHODS AND USES THEREOF" (EP Application No. 20205952.3) describes compounds that directly bind to AMPK through an allosteric drug and metabolite (ADaM) site formed at the interface between the AMPKα and AMPKβ subunits. These compounds are from substituted resorcinolone and directly activate AMPK in cells.
[0033] The AMPK activator can be a direct AMPK activator or an indirect AMPK activator. In one embodiment, the AMPK activator is a direct AMPK activator. In one embodiment, the AMPK activator is an indirect AMPK activator.
[0034] In one embodiment, AMPK activators may have potential as new therapeutic agents for these diseases.In one embodiment, one type of AMPK activator is a small molecule that mimics cellular AMP.
[0035] In one embodiment, the AMPK activator is cannabidiolic acid (CAS No. 1244-58-2), CBDA, CBGA, CBNA or any one of its derivatives. In one embodiment, the derivative is any one of the compounds having the general formula I.
[0036] In one embodiment, the AMPK activator is any one of cannabidiol, CBDA, CBGA, CBNA or a derivative thereof. In one embodiment, the derivative is any one of the compounds of formula I.
[0037] As used herein, the term "sodium-glucose cotransporter-2 inhibitor" or "SGLT2 inhibitor" refers to a compound or substance that exhibits an inhibitory effect on sodium-glucose cotransporter-2 (SGLT2), in particular on human SGLT2. The inhibitory effect on hSGLT2 measured by IC50 is preferably 1,000 nM or less, more preferably 100 nM or less and most preferably 50 nM or less. The IC50 value of SGLT2 inhibitors is generally greater than 0.01 nM, or even greater than 0.1 nM. The inhibitory effect on hSGLT2 can be measured by methods known in the literature, in particular as described in applications WO 2005 / 092877 or WO 2007 / 093610 (page 23 / 24); the documents are hereby incorporated by reference. The term "SGLT2 inhibitor" also includes pharmaceutically acceptable salts, hydrates and solvates thereof, including the corresponding crystalline forms.
[0038] In one embodiment, the SGLT2 inhibitor is selected from the group consisting of dapagliflozin, canagliflozin, empagliflozin, artigliflozin, resmogliflozin, sergliflozin, phlorizin, and derivatives thereof.
[0039] In one embodiment, SGLT2 inhibitors may include a class of prescription drugs that are approved by the FDA for diet and exercise to lower blood sugar in adults with type 2 diabetes. Drugs in the SGLT2 inhibitor class may include canagliflozin, dapagliflozin, and empagliflozin. They are available as single ingredient products and are also combined with other diabetes drugs such as metformin. SGLT2 inhibitors lower blood sugar by causing the kidneys to remove sugar from the body through urine.
[0040] Hsia et al. Curr Opin Endocrinol Diabetes Obes. 2017 Feb;24(1):73-79. doi:10.1097 / MED provides a series of compounds that act as SGLT2 inhibitors.
[0041] As used herein, the term "active ingredient" refers to any AMP-activated protein kinase (AMPK) activator (eg, CBDA, CBGA or CBNA) and / or SGLT2 inhibitor according to the present invention.
[0042] As used herein, the term "nutritional composition" or "nutritional supplement" refers to a nutritional product that provides an individual with nutrients that the individual may not otherwise consume in adequate amounts. For example, the nutritional composition or nutritional supplement of the present invention may include vitamins, minerals, fiber, fatty acids, or amino acids. The nutritional composition or nutritional supplement of the present invention may be provided, for example, in the form of a pill, tablet, lozenge, chewable capsule or tablet, tablet or capsule, or a powder supplement that can be dissolved in water or sprinkled on food.
[0043] In one embodiment, the nutritional composition or nutritional supplement of the present invention can provide selected nutrients without representing a significant portion of the overall nutritional requirements of the subject. Typically, they do not provide more than 0.1%, 1%, 5%, 10% or 20% of the daily energy requirements of the subject. The nutritional composition or nutritional supplement of the present invention can be used for any subject, such as a subject during pregnancy, for example as a maternal supplement.
[0044] As used herein, "effective amount" or "pharmaceutically effective amount", as used herein, refers to an amount that prevents a defect, treats a disease or medical condition in a subject, or more generally, refers to an amount that alleviates symptoms, manages the progression of a disease, or provides a nutritional, physiological or medical benefit to a subject. The relative terms "promote", "improve", "increase", "enhance", and the like refer to the effect of the compositions disclosed herein comprising an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA or CBNA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor relative to compositions that lack an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA or CBNA) and / or a sodium-glucose cotransporter-2 (SGLT2) inhibitor but are otherwise identical.
[0045] As used herein, the term "unit dosage form" refers to physically discrete units suitable as unit doses for human and animal subjects, each unit containing a predetermined amount of the nutritional composition disclosed herein, in an amount sufficient to produce the desired effect, preferably in combination with a pharmaceutically acceptable diluent, carrier or vehicle. The specifications of the unit dosage form depend on the specific compound used, the effect to be achieved, and the pharmacodynamics associated with each compound in the host. In one embodiment, the unit dosage form can be a predetermined amount of powder in a sachet.
[0046] As used herein, the term "nutritional product" refers to any product that can be used to provide nutrition to a subject. Typically, nutritional products contain a protein source, a carbohydrate source, and a lipid source.
[0047] As used herein, the term "food product" refers to any type of product that can be safely consumed by humans or animals. A food product can be in solid, semi-solid or liquid form and can contain one or more nutrients, foods or nutritional supplements. For example, a food product can additionally contain the following nutrients and micronutrients: a protein source, a lipid source, a carbohydrate source, vitamins and minerals. The food product can also contain an antioxidant, a stabilizer (when provided in solid form) or an emulsifier (when provided in liquid form).
[0048] As used herein, the term "functional food product" refers to a food product that provides additional health-promoting or disease-preventing functions to an individual.
[0049] As used herein, the term "healthy aging product" refers to a product that provides an individual with additional health promoting or disease preventing functions associated with healthy aging.
[0050] As used herein, the term "dairy product" refers to a food product produced from milk or milk components from animals such as cows, goats, sheep, yaks, horses, camels and other mammals. Examples of dairy products are low-fat milk (e.g., 0.1%, 0.5% or 1.5% fat), fat-free milk, milk powder, whole milk, whole milk products, butter, buttermilk, buttermilk products, skim milk, skim milk products, high milkfat products, condensed milk, crème brûlée, cheese, ice cream and dessert products, probiotic beverages or probiotic yogurt-type beverages.
[0051] As used herein, the term "dairy alternative product" refers to a product that is similar to dairy products but is not produced with milk.
[0052] As used herein, the term "milk" is defined by the Codex Alimentarius Commission as the normal mammary secretion of a dairy animal obtained from one or more milkings, without additions or extractions, intended for consumption as liquid milk or for further processing.
[0053] As used herein, the term "beverage product" refers to a nutritional product in liquid or semi-liquid form that can be safely consumed by an individual.
[0054] As used herein, the term "diet product" refers to a food product having a restricted and / or reduced caloric content.
[0055] As used herein, the term "pet food product" refers to a nutritional product intended for consumption by a pet. Pets or companion animals as referred to herein are understood to be animals selected from dogs, cats, birds, fish, rodents (such as mice, rats).
[0056] As used herein, an "effective amount" is an amount that prevents a defect, treats a disease or medical condition in an individual, or more generally, reduces symptoms, manages disease progression, or provides a nutritional, physiological or medical benefit to the individual.
[0057] All ingredients of the composition may be mixed together, or alternatively the composition may be provided in the form of a kit of parts, wherein the ingredients or groups of ingredients are provided separately. These separate compositions may be intended to be consumed separately or together.
[0058] Descriptions of simple chains such as methyl, pentyl, and dodecyl are known to those skilled in the art. For example, methyl is an alkyl group derived from methane containing one carbon atom bonded to three hydrogen atoms -CH3. Pentyl is a group having the chemical formula -C5H 11 The dodecyl group is a five-carbon alkyl functional group (substituent). 12 H 25 A dodecyl functional group (substituent).
[0059] In all structures, the dot indicates the insertion point of the chain on the aromatic ring.
[0060] For example, if in the Markush structure A, R2 is 3-methyl-2-buten-1-yl (1h), this corresponds to structure B:
[0061]
[0062] As used herein, the term "C5 isoprenoids" refers to the following substituents: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h) , 1,1-dimethyl-2-propene-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-butene-1-yl (1j), 4-hydroxy-3-methyl-2-butene-1-yl (1k), 1-hydroxy-3-methyl-2-butene-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p).
[0063]
[0064] As used herein, the term "C 10The term "isoprenoid" refers to the following substituents: 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3,7 -dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o).
[0065]
[0066] As used herein, the term "C 15 The term "isoprenoid" refers to the following substituents: 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d).
[0067]
[0068] As used herein, the term "C 20 "Isoprenoid" refers to the following substituents: 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadec-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b).
[0069]
[0070] As used herein, the term "alkyl" refers to a branched or unbranched saturated hydrocarbon chain having 1 to 20 carbon atoms, or 1 to 15 carbon atoms, or 1 to 10 carbon atoms, or 1 to 7 carbon atoms, or 1 to 5 carbon atoms, or 1 to 3 carbon atoms. The alkyl chain may be cyclic, in which case it will be referred to as a "cycloalkyl" group.
[0071] Non-limiting examples of branched or unbranched alkyl chains include: methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, heptyl, nonyl, decyl, undecyl, tetradecyl, pentadecyl, heptadecyl, eicosyl.
[0072] Non-limiting examples of cycloalkyl chains include: 5-methyl-2-(1-methylethyl)cyclohexyl(2o)
[0073] The term "substituted alkyl" refers to: 1) an alkyl chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of: alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, heterocyclylthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)2-alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2-heteroaryl. Unless otherwise defined, all substituents may be optionally further substituted by 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)2-alkyl. n R , where R is alkyl, aryl or heteroaryl and n is 0, 1 or 2; one oxygen substituent of an alkyl chain may be attached to two adjacent carbon atoms of the same alkyl chain by a single bond to form an epoxy group, ie, a three-membered epoxide ring.
[0074] Non-limiting examples of alkyl chains substituted with hydroxyl, alkoxy and / or acyloxy groups or containing epoxy groups include: 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 8-hydroxy-3,7-dimethyloctyl (2b), hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-Hydroxytridecyl (5e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), and 2-(acetoxy)tridecyl (5p).
[0075]
[0076]
[0077] Non-limiting examples of alkyl chains substituted with aryl / aryloxy groups include: benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e).
[0078]
[0079] Non-limiting examples of alkyl chains substituted with aryl / aryloxy and hydroxy groups include: 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b).
[0080]
[0081] Non-limiting examples of alkyl chains substituted with heterocyclyl groups include: tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a).
[0082]
[0083] or
[0084] 2) an alkyl chain as defined above interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)n R Further substituted, wherein R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0085] or
[0086] 3) an alkyl chain as defined above, having 1, 2, 3, 4 or 5 substituents as defined above, and further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0087] or
[0088] 4) An alkyl chain as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0089] Non-limiting examples of alkyl chains in which one or more of the methylene groups are replaced with a carbonyl group include: 3-methyl-2-oxobutyl (1g), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 2-oxotridecyl (9h).
[0090]
[0091] or
[0092] 5) an alkyl chain as defined above, wherein one of the methylene groups is replaced by a carbonyl group to give an oxo group, and having 1, 2, 3, 4 or 5 substituents as defined above, or interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or having 1, 2, 3, 4 or 5 substituents as defined above and also interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0093] Non-limiting examples of alkyl chains in which one methylene group is replaced with a carbonyl group to produce an oxo group and having a hydroxy substituent include: 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecanyl (10b).
[0094]
[0095] Non-limiting examples of aryl / aryloxy substituted alkyl chains in which one methylene group is replaced by a carbonyl group to produce an oxo group include: 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b).
[0096]
[0097] As used herein, the term "alkenyl" refers to a class of alkyl chains as defined above in which two atoms of the alkyl chain form a double bond that is not part of an aromatic group. That is, the alkenyl chain comprises the formula RC(R)=C(R)-R, and in one embodiment, R refers to the remainder of the alkenyl chain, which may be the same or different. The alkenyl portion may be branched, straight chain or cyclic (in which case it will also be referred to as a "cycloalkenyl" group).
[0098] The term "substituted alkenyl" refers to:
[0099] 1) an alkenyl chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, hetero Cyclicthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)2-alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2-heteroaryl. Unless otherwise defined, all substituents may be optionally further substituted by 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)n R , where R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0100] One oxygen substituent of an alkenyl chain can be attached to two adjacent carbon atoms of the same alkenyl chain via single bonds to form an epoxy group, ie, a three-membered epoxide ring.
[0101] or
[0102] 2) an alkenyl chain as defined above interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)n R Further substituted, wherein R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0103] or
[0104] 3) an alkenyl chain as defined above, having 1, 2, 3, 4 or 5 substituents as defined above, and further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0105] or
[0106] 4) Alkenyl chains as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0107] or
[0108] 5) an alkenyl chain as defined above, in which one methylene group is substituted by a carbonyl group to give an oxo group, and having 1, 2, 3, 4 or 5 substituents as defined above, or interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or having 1, 2, 3, 4 or 5 substituents as defined above, and also interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0109] Non-limiting examples of alkenyl chains include: 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g).
[0110]
[0111] Non-limiting examples of alkenyl chains substituted with hydroxyl and / or acyloxy groups or containing epoxy groups include: 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl(geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 10-(acetyloxy)-8-pentadecenyl (13a).
[0112]
[0113] Non-limiting examples of alkenyl chains substituted with aryl groups include: 2-phenylethenyl (14a).
[0114]
[0115] Non-limiting examples of alkenyl chains in which one methylene group is replaced with an oxo group include: 1-hydroxymethylene-2-oxopropyl (15a).
[0116]
[0117] As used herein, the term "alkynyl" refers to a class of alkyl chains as defined above in which two atoms of the alkyl chain form a triple bond. That is, the alkynyl chain comprises the formula RC≡CR, and in one embodiment, R refers to the remainder of the alkynyl chain, which may be the same or different. Non-limiting examples of alkynyl chains include -C≡CH, -C≡C-CH3, and -C≡C-CH2-CH3. The "R" portion of the alkynyl moiety may be branched, straight or cyclic. The alkynyl chain may be optionally substituted.
[0118] The term "substituted alkynyl" refers to:
[0119] 1) an alkynyl chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, hetero Cyclicthio, thiol, alkylthio, aryl, aryloxy, heteroaryl, aminosulfonyl, aminocarbonylamino, heteroaryloxy, heterocyclyl, heterocyclyloxy, hydroxyamino, alkoxyamino, nitro, -S(O)-alkyl, -S(O)-cycloalkyl, -S(O)-heterocyclyl, -S(O)-aryl, -S(O)-heteroaryl, -S(O)2-alkyl, -S(O)2-cycloalkyl, -S(O)2-heterocyclyl, -S(O)2-aryl and -S(O)2-heteroaryl. Unless otherwise defined, all substituents may be optionally further substituted by 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)nR , where R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0120] One oxygen substituent of an alkynyl chain can be attached to two adjacent carbon atoms of the same alkynyl chain via single bonds to form an epoxy group, ie, a three-membered epoxide ring.
[0121] or
[0122] 2) an alkynyl chain as defined above interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)n R Further substituted, wherein Ris alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0123] or
[0124] 3) an alkynyl chain as defined above, having 1, 2, 3, 4 or 5 substituents as defined above, and further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0125] or
[0126] 4) Alkynyl chains as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0127] or
[0128] 5) An alkynyl chain as defined above, in which one methylene group is substituted by a carbonyl group to give an oxo group, and having 1, 2, 3, 4 or 5 substituents as defined above, or interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or having 1, 2, 3, 4 or 5 substituents as defined above, and also interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0129] As used herein, the term "polyalkenyl" refers to a chain in which more than one pair of atoms of an alkyl group form a double bond that is not part of an aromatic group. That is, the polyalkenyl chain contains 2 to 8 RC(R)=C(R)-R chemical formulas, and in one embodiment, R refers to the rest of the alkenyl chain, which may be the same or different. The polyalkenyl moiety may be branched or straight chain.
[0130] Non-limiting examples of polyalkenyl chains include: 3-methyl-1,3-butadienyl (1p), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), (2E,6E,10E)-3,7,11,15-tetramethylhexadecane-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b), 8,11-heptadecadien-1-yl (16a).
[0131]
[0132] The polyalkenyl moiety containing two double bonds may be cyclic (in which case it will also be referred to as a "cycloalkadienyl" group). Non-limiting examples of cycloalkadienyl groups include cyclopentadiene and cyclohexadiene groups. The polyalkenyl chain may be optionally substituted.
[0133] As used herein, the term "substituted polyalkenyl" refers to:
[0134] 1) a polyalkenyl chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, alkyl, -S(O)-2- alkyl, -S(O)-2- cycloalkyl, -S(O)-2-heterocyclyl, -S(O)-2-aryl and -S(O)-2-heteroaryl. Unless otherwise defined, all substituents may be optionally further substituted by 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)-2- alkyl. n R , where R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0135] One oxygen substituent of a polyalkenyl chain can be attached to two adjacent carbon atoms of the same polyalkenyl chain by a single bond to form an epoxy group, i.e., a three-membered epoxide ring. One oxygen substituent of a polyalkenyl chain can form a five-membered aromatic ring having four carbon atoms in the same chain, thereby producing a furan ring.
[0136] or
[0137] 2) a polyalkenyl chain as defined above interrupted by 1 to 5 atoms (e.g., 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxyl, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O). n R Further substituted, wherein R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0138] or
[0139] 3) a polyalkenyl chain as defined above having 1, 2, 3, 4 or 5 substituents as defined above and further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0140] or
[0141] 4) A polyalkenyl chain as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0142] or
[0143] 5) a polyalkenyl chain as defined above, in which one methylene group is substituted by a carbonyl group to obtain an oxo group, and having 1, 2, 3, 4 or 5 substituents as defined above, or interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or having 1, 2, 3, 4 or 5 substituents as defined above, and also interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0144] Non-limiting examples of polyalkenyl chains substituted with hydroxyl groups or containing a furan ring include: 5-hydroxy-3,7-dimethyl-2,6-octadienyl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methyl-1-propen-1-yl)-3-furanyl]-2-hexen-1-yl (3d).
[0145] Non-limiting examples of linear or cyclic polyalkenyl chains in which one methylene group is replaced by a carbonyl group to produce an oxo group include: 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c).
[0146]
[0147] Non-limiting examples of polyalkenyl chains substituted with aryloxy groups include 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a).
[0148]
[0149] The term polyalkynyl refers to a chain in which more than one pair of atoms of an alkyl group form a triple bond. That is, the polyalkynyl chain comprises 2 to 8 RC≡CR chemical formulas, and in one embodiment, R refers to the remainder of the alkynyl chain, which may be the same or different. Non-limiting examples of polyalkynyl chains include -CH2-CH2-C≡CC≡CH. The "R" portion of the polyalkynyl moiety may be branched, straight or cyclic.
[0150] As used herein, the term "substituted polyalkynyl" refers to:
[0151] 1) a polyalkynyl chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxy, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, alkyl, -S(O)- ... , where R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0152] or
[0153] 2) a polyalkynyl chain as defined above interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxyl, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O). n R Further substituted, wherein R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0154] or
[0155] 3) a polyalkynyl chain as defined above having 1, 2, 3, 4 or 5 substituents as defined above and further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0156] or
[0157] 4) A polyalkynyl chain as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0158] or
[0159] 5) A polyalkynyl chain as defined above, in which one methylene group is substituted by a carbonyl group to give an oxo group, and which has 1, 2, 3, 4 or 5 substituents as defined above, or is interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or which has 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0160] As used herein, the term "polyunsaturated" refers to a chain in which at least one pair of atoms of the alkyl chain forms a double bond and a pair of atoms of the alkyl chain forms a triple bond. That is, the polyunsaturated chain comprises the formulas RC(R)=C(R)-R and RC≡CR, and in one embodiment, R refers to the remainder of the polyunsaturated chain, which may be the same or different, and the total number of unsaturated bonds may vary from 2 to 8. Non-limiting examples of this type of polyunsaturated chain include -CH2-CH=CH-C≡CH. The "R" portion of the polyunsaturated portion may be branched, linear or cyclic.
[0161] As used herein, the term "substituted polyunsaturated" refers to:
[0162] 1) a polyunsaturated chain as defined above having 1, 2, 3, 4 or 5 substituents (in some embodiments, 1, 2 or 3 substituents) selected from the group consisting of alkyl; alkenyl, alkynyl, alkoxy, cycloalkyl, cycloalkenyl, cycloalkyloxy, cycloalkenyloxy, acyl, amide, acyloxy, amino, substituted amino, aminocarbonyl, alkoxycarbonylamino, azido, cyano, halogen, hydroxyl, keto, thiocarbonyl, carboxyl, carboxyalkyl, arylthio, heteroarylthio, alkyl, -S(O)-2- alkyl, -S(O)-2- cycloalkyl, -S(O)-2-heterocyclyl, -S(O)-2-aryl and -S(O)-2-heteroaryl. Unless otherwise defined, all substituents may be optionally further substituted by 1, 2 or 3 substituents selected from alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)-2- alkyl. n R , where R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0163] or
[0164] 2) a polyunsaturated chain as defined above interrupted by 1 to 5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) independently selected from oxygen, sulfur and NR , where R is selected from the group consisting of hydrogen, alkyl, cycloalkyl, alkenyl, cycloalkenyl, alkynyl, aryl, heteroaryl and heterocyclyl. All substituents may be optionally replaced by alkyl, alkenyl, alkynyl, carboxyl, carboxyalkyl, aminocarbonyl, hydroxy, alkoxy, halogen, CF3, amino, substituted amino, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl and -S(O)n R Further substituted, wherein R is alkyl, aryl or heteroaryl, and n is 0, 1 or 2;
[0165] or
[0166] 3) a polyunsaturated chain as defined above, which simultaneously has 1, 2, 3, 4 or 5 substituents as defined above and is further interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above;
[0167] or
[0168] 4) A polyunsaturated chain as defined above, wherein one or more of the methylene groups are substituted by a carbonyl group to give an oxo group.
[0169] or
[0170] 5) A polyunsaturated chain as defined above, in which one methylene group is substituted by a carbonyl group to give an oxo group, and which has 1, 2, 3, 4 or 5 substituents as defined above, or is interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above, or which has 1, 2, 3, 4 or 5 substituents as defined above and is also interrupted by 1-5 atoms (e.g. 1, 2, 3, 4 or 5 atoms) as defined above.
[0171] As used herein, the term "ring" refers to any covalently closed structure. Rings include, for example, carbocycles (e.g., aryl and cycloalkyl), heterocycles (e.g., heteroaryl and non-aromatic heterocycles), aromatics (e.g., aryl and heteroaryl), and non-aromatics (e.g., cycloalkyl and non-aromatic heterocycles). Rings can be optionally substituted. Rings can form part of a ring system. As used herein, the term "ring system" refers to two or more rings, and in one embodiment, two or more rings are fused. As used herein, the term "fused" refers to a structure in which two or more rings share one or more bonds.
[0172] As used herein, the term "halogen" refers to a fluorine atom, a chlorine atom, a bromine atom, or an iodine atom.
[0173] As used herein, the term "glycoside" refers to a compound in which at least one sugar is bound to another functional group via a glycosidic bond. Typically, the glycosidic chain may contain from 1 to 4 sugar units.
[0174] As used herein, the term "glycosidic bond" refers to a bond formed between a hemiacetal or hemiketal group of a sugar and a chemical group of a compound. The chemical group may be -OH (O-glycoside) or -CR1R2R3 (C-glycoside).
[0175] The terms "acylated O-glycosides" and "acylated C-glycosides" refer to compounds in which at least one hydroxyl group of the glycosidic chain is esterified with an organic acid. Typical examples of organic acids may include acetic acid, substituted benzoic acid, cinnamic acid (caffeic acid, ferulic acid, p-coumaric acid) and / or phenylpropionic acid (dihydrocaffeic acid).
[0176] The terms "sulfated O-glycoside" and "sulfated C-glycoside" refer to compounds in which at least one of the hydroxyl groups of the glycosidic chain is sulfated.
[0177] As used herein, the term "methylenedioxy" refers to a functional group having the structural formula RO-CH2-O-R', which is attached to the rest of the molecule by two chemical bonds.
[0178] As used herein, the term "analog" refers to a compound that has a structure similar to another structure, but differs therefrom in certain components. As used herein, the term "derivative" refers to any compound that can be conceivably produced or actually synthesized from a parent compound by replacing one or more atoms with another atom or group of atoms.
[0179] It should be understood that according to certain embodiments, the compounds of the present invention or compositions thereof can be nutraceutical compositions, pharmaceutical compositions, functional foods, functional nutritional products, medical foods, medical nutritional products, or dietary supplements.
[0180] The term "nutraceutical" combines the words "nutrition" and "drug" together. It is a food or food product that provides health and medical benefits, including the prevention and treatment of a condition, disorder, or disease. Nutraceuticals are products that are isolated or purified from foods that are typically sold as drugs that are not usually associated with food. Nutraceuticals are shown to have physiological beneficial effects or provide prevention of chronic conditions, disorders, or diseases. Such products can range from isolated nutrients, dietary supplements, and special diets to genetically engineered foods, herbal products, and processed foods such as cereals, soups, and beverages.
[0181] As used herein, the term "nutraceutical" indicates usefulness in the fields of nutrition and pharmaceutical applications. Thus, the novel nutritional composition can be used as a supplement to food and beverages, and can be used as a pharmaceutical preparation for enteral or parenteral administration, which can be a solid preparation such as a capsule or tablet, or a liquid preparation such as a solution or suspension.
[0182] The nutraceutical composition according to the present invention may also comprise protective hydrophilic colloids (such as gums, proteins, modified starches), binders, film formers, encapsulating agents / materials, wall / shell materials, matrix compounds, coatings, emulsifiers, surfactants, solubilizers (oils, fats, waxes, lecithins, etc.), adsorbents, carriers, fillers, co-compounds, dispersants, wetting agents, processing aids (solvents), flow agents, taste masking agents, weighting agents, gelling agents, gel forming agents, antioxidants and antimicrobial agents.
[0183] In addition, multivitamin and mineral supplements can be added to the nutritional composition of the present invention to obtain sufficient amounts of essential nutrients that are missing in some diets. Multivitamin and mineral supplements can also be used to prevent disease and prevent nutritional losses and deficiencies due to lifestyle patterns.
[0184] The nutraceutical composition of the invention may be in any galenic dosage form suitable for administration to the body, in particular any form conventionally used for oral administration, for example in solid form, such as food or feed, food or feed premix, fortified food or feed, tablet, pill, granule, dragee, capsule and effervescent preparations such as powder and tablet; or in liquid form, such as solution, emulsion or suspension, such as, for example, beverage, paste and oily suspension. The paste may be incorporated into a hard or soft shell capsule, whereby the capsule is characterized by a matrix of, for example, (fish, pig, poultry, cattle) gelatin, vegetable protein or lignin sulfonate. Examples of other application forms are those for transdermal, parenteral or injection administration. Dietary and pharmaceutical compositions may be in the form of controlled (slow release) preparations.
[0185] Beverages include non-alcoholic beverages and alcoholic beverages and liquid preparations to be added to drinking water and liquid foods. Non-alcoholic beverages are, for example, soft drinks, sports drinks, fruit juices, teas, and milk-based beverages. Liquid foods are, for example, soups and dairy products. The nutritional composition comprising the compounds of the present invention can be added to soft drinks, energy bars, or candies.
[0186] If the nutraceutical composition is a pharmaceutical preparation, and the composition further comprises a pharmaceutically acceptable excipient, diluent or adjuvant, then standard techniques may be used for its formulation, as disclosed, for example, in Remington's Pharmaceutical Sciences, 20th edition, Williams & Wilkins, PA, USA. For oral administration, tablets and capsules containing suitable binders (e.g., gelatin or polyvinyl pyrrolidone), suitable fillers (e.g., lactose or starch), suitable lubricants (e.g., magnesium stearate), and optionally other additives are preferably used.
[0187] As used herein, the terms "functional food", "functional nutritional product", "medical food" or "medical nutritional product" refer to any health food that claims to have health-promoting or disease-preventing properties beyond the basic function of supplying nutrients. The general category of functional foods includes processed foods or foods fortified with additives that promote health, such as "vitamin-enriched" products.
[0188] The terms "food", "food product" and "food composition" or "dietary product" mean a product or composition that is intended for ingestion by an individual (such as a human) and that provides at least one nutrient to the individual. The compositions of the present disclosure (including the various embodiments described herein) may comprise, consist of, or consist essentially of the following elements: the elements disclosed herein, as well as any additional or optional ingredients, components, or elements described herein or that can be used in a diet.
[0189] Dietary supplements, also known as food supplements or nutritional supplements, are preparations designed to supplement the diet and provide nutrients (such as vitamins, minerals, fiber, fatty acids or amino acids) that may be missing or may be inadequately consumed in a person's diet. Some countries define dietary supplements as foods, while other countries define dietary supplements as medicines or natural health products. Supplements containing vitamins or dietary minerals are included as a category of food in the Codex Alimentarius, which is an internationally recognized collection of standards, codes of practice, guidelines and other recommendations related to food, food production and food safety. These texts are developed by the Codex Alimentarius Commission, an organization funded by the Food and Agriculture Organization of the United Nations (FAO) and the World Health Organization (WHO).
[0190] Compositions intended for animals include food compositions that provide necessary dietary needs for animals, animal rewards (e.g., biscuits) and / or dietary supplements. Compositions can be dry compositions (e.g., coarsely ground food), semi-wet compositions, wet compositions, or any mixture thereof. In one embodiment, the composition is a dietary supplement, such as gravy, drinking water, beverage, yogurt, powder, granule, paste, suspension, chew, small pieces of food, rewards, snacks, pellets, pills, capsules, tablets, or any other suitable delivery form. Dietary supplements can include high concentrations of UFA and NORC, as well as B vitamins and antioxidants. This allows supplements to be administered to animals in small amounts, or can be diluted before being administered to animals in an alternative. Dietary supplements may need to be mixed, or can be mixed with water or other diluents before being administered to animals.
[0191] A "pet food" or "pet treat composition" contains about 15% to about 50% crude protein. The crude protein material may include plant proteins such as soy meal, soy protein concentrate, corn gluten meal, wheat gluten, cottonseed and peanut meal, or animal proteins such as casein, albumin and meat protein. Examples of meat proteins that can be used in the present invention include pork, lamb, horse, poultry, fish and mixtures thereof. The composition may also contain about 5% to about 40% fat. The composition may also contain a carbohydrate source. The composition may contain about 15% to about 60% carbohydrates. Examples of such carbohydrates include grains or cereals such as rice, corn, millet, sorghum, alfalfa, barley, soybeans, canola, oats, wheat and mixtures thereof. The composition may also optionally include other materials such as dried whey and other dairy by-products.
[0192] As used herein, the term "diabetes" includes insulin-dependent diabetes mellitus (i.e., IDDM, also known as type 1 diabetes), non-insulin-dependent diabetes mellitus (i.e., NIDDM, also known as type 2 diabetes), and prediabetes. Type 1 diabetes is the result of an absolute lack of insulin, a hormone that regulates glucose utilization. Type 2 diabetes usually occurs in the face of normal or even elevated insulin levels, and appears to be the result of the inability of tissues to respond appropriately to insulin. This is called "insulin resistance." Most patients with type 2 diabetes are also overweight or obese. One of the criteria for diagnosing diabetes is the fasting plasma glucose level. A diabetic subject has a fasting plasma glucose level greater than or equal to 126 mg / dl. A prediabetic subject is a person with prediabetes. A prediabetic subject is a subject with impaired fasting glucose (fasting plasma glucose level greater than or equal to 100 mg / dl and less than 126 mg / d1); or a subject with impaired glucose tolerance (2-hour plasma glucose level>140 mg / d1 and less than 200 mg / dl); or a subject with increased risk of developing diabetes due to insulin resistance. Preventing type 2 diabetes includes treating prediabetes.
[0193] As used herein, the term "dyslipidemia" encompasses abnormal levels of any lipid fraction as well as specific lipoprotein abnormalities. For example, it refers to an increase in plasma cholesterol and / or an increase in triglycerides and / or an increase in free fatty acids and / or low high-density lipoprotein (HDL) levels and / or high low-density lipoprotein (LDL) levels and / or high very low-density lipoprotein (VLDL) levels. Dyslipidemia can, for example, lead to the development of atherosclerosis and ultimately symptomatic vascular disease (including coronary heart disease). Dyslipidemia may or may not be associated with diabetes.
[0194] As used herein, the term "metabolic disorder" encompasses any abnormal chemical and enzymatic reactions that disrupt normal metabolism due to environmental and genetic factors (environmental factors include physical activity, nutrition), resulting in excessive levels or deficiencies of certain substances and dysfunction of energy homeostasis. Non-limiting examples of metabolic disorders include diabetes, dyslipidemia, hypertension, overweight, obesity, and any combination thereof.
[0195] As used herein, the term "AMPK-related disease" includes pathological or etiological conditions in which activation of AMPK provides a beneficial effect. Examples of such diseases or conditions include obesity, diabetes, metabolic syndrome, acute inflammatory lung injury, heart disease, reperfusion ischemia, cancer, aging, retinal degeneration, cardiac hypertrophy, non-alcoholic fatty liver disease, hypertension, albuminuria, sporadic Alzheimer's disease, muscular dystrophy, and osteoarthritis. In addition, the term "AMPK-related condition" includes conditions in which activation of AMPK improves the condition associated with the primary "AMPK-related disease". For example, diabetic nephropathy (Salotto et al., (2017) J. Pharma and Expt Thera 361: 303-311) or diabetic neuropathy are "AMPK-related conditions" that may be associated with "AMPK-related diseases" of diabetes.
[0196] As used herein, the terms "prevention" or "preventing" refer to reducing the risk and / or severity of a condition, disorder or disease.
[0197] As used herein, the terms "treatment / treating / treat", "alleviate" or "alleviate" refer to preventive or prophylactic treatment (preventing and / or slowing the development of a target pathological condition or disorder) and also include curative, therapeutic or disease-modifying treatments, including therapeutic measures that cure, slow down, alleviate the symptoms of a diagnosed confirmed pathological condition or disorder and / or interrupt its progression; and include treating patients who are at risk of contracting a disease or suspected of having contracted a disease, as well as treating patients who are sick or have been diagnosed with a disease or medical condition. The term does not necessarily mean that the subject is treated until full recovery. These terms also refer to health maintenance and / or promotion in subjects who do not have a disease but may be prone to developing an unhealthy condition. These terms are also intended to include strengthening or otherwise enhancing one or more primary preventive or therapeutic measures. The terms "treatment", "alleviate" and "alleviate" are also intended to include dietary management of a disease or condition or dietary management that prevents or prevents a disease or condition. Treatment can be patient-related or doctor-related.
[0198] Obesity is an excess of body fat relative to lean body mass and is a highly prevalent chronic disease in modern societies. It is associated not only with social stigma but also with shortened lifespan and numerous medical problems, including adverse psychological development, coronary artery disease, hypertension, stroke, diabetes, hyperlipidemia, and some cancers (see, e.g., Nishina et al., Metab. 43:554-558, 1994; Grundy and Barnett, Dis. Mon. 36:641-731, 1990; Rissanen et al., British Medical Journal, 301:835-837, 1990).
[0199] As used herein, the term "obesity-related conditions" refers to those diseases or conditions in which excess body weight or an elevated "body mass index (BMI)" is associated with the progression or inhibition of a disease or condition. Representative examples of obesity-related conditions include, but are not limited to, diabetes, diabetic complications, insulin sensitivity, polycystic ovarian disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia, and cerebrovascular dementia. See, Harrison's Principles of Internal Medicine, 13th Edition, McGraw Hill Companies Inc., New York (1994). Examples of inflammatory conditions include, but are not limited to, diseases of the digestive organs (such as ulcerative colitis, Crohn's disease, pancreatitis, gastritis, benign tumors of the digestive organs, digestive polyps, hereditary polyposis syndromes, colon cancer, rectal cancer, gastric cancer and ulcerative diseases of the digestive organs), angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia, cerebrovascular dementia, immune diseases and general cancers.
[0200] As used herein, the terms "subject", "individual" or "patient" refer to any animal, including humans, that can benefit from one or more of the compounds, compositions or methods disclosed herein. Generally, the subject is a human or an avian, bovine, canine, equine, feline, caprine, wolf, murine, ovine and porcine animal. As used herein, "companion animal" refers to any domesticated animal, and includes, but is not limited to, cats, dogs, rabbits, guinea pigs, ferrets, hamsters, mice, gerbils, horses, cattle, goats, sheep, donkeys, pigs, and the like. Preferably, the subject is a human or a companion animal, such as a dog or a cat. In the case of humans, the term "elderly" refers to an age of at least 60 years old, preferably over 63 years old, more preferably over 65 years old, and most preferably over 70 years old since birth. In the context of humans, the term "middle-aged and elderly" refers to an age of at least 45 years old, preferably over 50 years old, more preferably over 55 years old, since birth, and includes elderly subjects. For other animals, "old age" means having exceeded 50% of the average life span for its particular species and / or breed within a species. An animal is considered "old" if it has exceeded 66% of the average life expectancy, preferably has exceeded 75% of the average life expectancy, and more preferably has exceeded 80% of the average life expectancy. A senior cat or dog is at least about 7 years old since birth.
[0201] In one embodiment, as used herein, the term "subject" refers to a mammal. Mammals include, but are not limited to, rodents, aquatic mammals, domestic animals (such as dogs and cats), farm animals (such as sheep, pigs, cattle and horses), and humans. In one embodiment, the mammal can be a cat, a dog, or a human. The human can be a female, for example, a female who is trying to become pregnant or is already pregnant. In one embodiment of the invention, the subject is a mammal selected from the group consisting of a cat, a dog, and a human. For example, the subject can be an elderly person.
[0202] As used herein, the term "empagliflozin" refers to an antidiabetic drug (sold under brand names such as Jardiance) used to improve glucose control in people with type 2 diabetes, to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease, to reduce the risk of death and hospitalization in people with heart failure and low ejection fraction, and to reduce the risk of cardiovascular death and hospitalization for heart failure in adults. It can be prescribed instead of metformin and has benefits over sulfonylureas. It can be used with other drugs such as metformin or insulin. It may not be recommended for type 1 diabetes. Empagliflozin is an inhibitor of sodium glucose cotransporter-2 (SGLT-2) and works by increasing sugar losses in the urine. The IUPAC name of empagliflozin is (2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol.
[0203] As used herein, the term "canagliflozin" refers to a drug (sold under brand names such as Invokana) for the treatment of type 2 diabetes. It is a third-line drug tried after metformin, which is a first-line drug for type 2 diabetes. It is used with exercise and diet. It is not recommended for use in type 1 diabetes. Canagliflozin is a sodium-glucose cotransporter-2 (SGLT2) inhibitor. It works by increasing the amount of glucose lost in urine. The IUPAC name of canagliflozin is (2S, 3R, 4R, 5S, 6R)-2-{3-[5-[4-fluoro-phenyl)-thiophene-2-ylmethyl]-4-methyl-phenyl}-6-hydroxymethyl-tetrahydro-pyran-3,4,5-triol.
[0204] As used herein, the term "dapagliflozin" or "Dapa" refers to a drug used to treat type 2 diabetes (sold under brand names such as Farxiga (US) and Forxiga (EU)). It is also used to treat adults with certain types of heart failure and chronic kidney disease. Dapagliflozin is a sodium-glucose cotransporter-2 (SGLT-2) inhibitor and works by removing sugar from the body along with urine. The IUPAC name of dapagliflozin is (2S, 3R, 4R, 5S, 6R)-2-[4-chloro-3-(4-ethoxybenzyl)phenyl]-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol.
[0205] As used herein, the term "Egliflozin" refers to a drug used to treat type 2 diabetes (sold under the brand name Steglatro). Egliflozin is a sodium / glucose co-transporter-2 (SGLT2) inhibitor and belongs to a class of drugs known as gliflozins. The IUPAC name of Egliflozin is (1S, 2S, 3S, 4R, 5S)-5-[4-chloro-3-(4-ethoxybenzyl)phenyl]-1-(hydroxymethyl)-6,8-dioxabicyclo[3.2.1]octane-2,3,4-triol.
[0206] As used herein, the term "phlorizin" refers to the glucoside of phlorizin (a dihydrochalcone). White solid samples are usually yellow due to impurities. It has a sweet taste and contains four molecules of water in the crystal. Above 200°C, it decomposes to produce rutin. It is poorly soluble in ether and cold water, but soluble in ethanol and hot water. After long-term exposure to aqueous solution, phlorizin is hydrolyzed into phlorizin and glucose. The IUPAC name of phlorizin is 1-(2,4-dihydroxy-6-{[(2S, 3R, 4S, 5S, 6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxane-2-yl]oxy}phenyl)-3-(4-hydroxyphenyl)propan-1-one. It is also known as Isosalipurposide.
[0207] Implementation
[0208] Composition
[0209] One aspect of the present disclosure is a composition for synergistically activating AMPK and improving metabolic health (e.g., treating or preventing metabolic disorders or obesity-related conditions), the composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or a derivative or analog thereof) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0210] Applicants surprisingly discovered that administration of a composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or their derivatives or analogs) and a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a subject in need thereof resulted in improved expression of activated AMPK, thereby synergistically activating AMPK to improve metabolic health, compared to administration of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or their derivatives or analogs) or a sodium-glucose co-transporter-2 (SGLT2) inhibitor alone. For example, the applicant surprisingly discovered that administration of a composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or their derivatives or analogs) and a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a subject can result in an overall improvement of at least 1% in glucose clearance in the subject, compared to administration of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or their derivatives or analogs) or a sodium-glucose co-transporter-2 (SGLT2) inhibitor alone. Further, the applicant surprisingly discovered that administration of a composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA) and a sodium-glucose co-transporter-2 (SGLT2) inhibitor to a subject can result in an overall improvement of at least 1% in glucose clearance in the subject, compared to the total effect of the AMP-activated protein kinase (AMPK) activator (e.g., CBDA, CBGA, CBNA, or their derivatives or analogs) and a sodium-glucose co-transporter-2 (SGLT2) inhibitor on glucose clearance.
[0211] In one aspect, the present disclosure relates to a composition for activating AMPK in a subject, the composition comprising a first compound and a second compound. The subject is a mammal, such as a cat, a dog, or a human. In one embodiment, the subject is a female human or a male human. In a preferred embodiment, the subject is an elderly female human or an elderly male human.
[0212] In one embodiment, the first compound is an AMP-activated protein kinase (AMPK) activator or a derivative thereof. In one embodiment, the second compound is a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a derivative thereof.
[0213] In one embodiment, the first compound is a direct AMP-activated protein kinase (AMPK) activator or a derivative thereof. In one embodiment, the second compound is a sodium-glucose cotransporter-2 (SGLT2) inhibitor selected from the group consisting of dapagliflozin, canagliflozin, empagliflozin, atiagliflozin, repagliflozin, sergliflozin, phlorizin and their derivatives.
[0214] In one embodiment, the first compound is a substituted resorcinol or a derivative thereof that is a direct AMP-activated protein kinase (AMPK) activator. In one embodiment, the second compound is a sodium-glucose cotransporter-2 (SGLT2) inhibitor selected from the group consisting of dapagliflozin, canagliflozin, empagliflozin, atiagliflozin, repagliflozin, sergliflozin, phlorizin and their derivatives.
[0215] In one embodiment, the composition is used to activate AMPK, and the composition comprises a first compound; and a second compound; wherein the first compound has the general formula I,
[0216]
[0217] wherein R1 and R3 are each independently OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate;
[0218] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0219] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0220] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 Polyalkynyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof;
[0221] The second compound is a sodium-glucose co-transporter-2 (SGLT2) inhibitor.
[0222] In one embodiment, the sodium-glucose cotransporter-2 (SGLT2) inhibitor is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin and erpagliflozin.
[0223] In one embodiment, the sodium-glucose cotransporter-2 (SGLT2) inhibitor is selected from the group consisting of empagliflozin, canagliflozin, phlorizin, and dapagliflozin.
[0224] In one embodiment, the sodium-glucose cotransporter-2 (SGLT2) inhibitor comprises dapagliflozin.
[0225] In one embodiment, the sodium-glucose cotransporter-2 (SGLT2) inhibitor is dapagliflozin.
[0226] In one embodiment, the sodium-glucose cotransporter-2 (SGLT2) inhibitor is phlorizin.
[0227] In one embodiment, the first compound has the general formula I,
[0228]
[0229] in:
[0230] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; or sulfated O-glycoside;
[0231] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 10 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0232] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0233] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkynyl; optionally, the OCH3 group may be cyclized with an adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof.
[0234] In one embodiment, the first compound has the general formula I,
[0235]
[0236] in:
[0237] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; or acylated O-glycoside;
[0238] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C 10 To C 20 optionally substituted and / or optionally branched C 10 To C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0239] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0240] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally branched C1 to C 20 Alkyl; optionally branched C2 to C 20 Alkenyl; optionally branched C4 to C 20 Polyalkenyl; optionally branched C2 to C 20 Alkynyl, or an optionally branched C4 to C 20 polyalkynyl; optionally, the OCH3 group may be cyclized with an adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof.
[0241] In another embodiment, the first compound has the general formula I,
[0242]
[0243] in:
[0244] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; or acylated O-glycoside;
[0245] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0246] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne;
[0247] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkynyl; optionally, the OCH3 group may be cyclized with an adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof.
[0248] In another embodiment, the first compound has the general formula I,
[0249]
[0250] in:
[0251] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate;
[0252] R2 is CH3, OH; O-glycoside; C-glycoside; sulfated O-glycoside; sulfated C-glycoside; chlorine; CHO (aldehyde); sulfate; optionally substituted and / or optionally branched C2 to C 15 or optionally substituted and / or optionally branched C4 to C 15 Polyene;
[0253] R4 is: H; CH3, OH; OCH3; chlorine or 3,3-dimethylallyl chain (1h);
[0254] R5 is: H; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 or optionally substituted and / or optionally branched C4 to C 20 polyenyl; optionally, the OCH3 group may be cyclized with an adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof.
[0255] In one embodiment, the first compound has the general formula I,
[0256]
[0257] in:
[0258] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate;
[0259] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl ( 1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methyl-1-propen-1-yl)-3-furanyl]-2-hexen-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a);
[0260] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3 -methylbutyl (1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E)-3, 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2.j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadien-1-yl (2m), 3,7-dimethyl-5-oxo-2,6-octadien-1 (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a substituted alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (1 0b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chain selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a);
[0261] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; a C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl ( 1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group may be cyclized with the adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof. ;
[0262] In another embodiment, the first compound has the general formula I,
[0263]
[0264] in:
[0265] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate;
[0266] R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl Butyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 An isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a substituted alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) , 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); a substituted alkenyl chain selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of: 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a);
[0267] R4 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl -2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of: 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a);
[0268] R5 is: H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl butyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); a substituted alkenyl chain selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group may be cyclized with the adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof. ;
[0269] In another embodiment, the first compound has the general formula I,
[0270]
[0271] in:
[0272] R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate;
[0273] R2 is CH3, OH; O-glycoside; C-glycoside; sulfated O-glycoside; sulfated C-glycoside; chlorine; CHO (aldehyde); sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-buten-1-yl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); a C10 isoprenoid chain selected from the group consisting of: 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl ( C, nerolidol (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavenderyl) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadienyl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 an isoprenoid chain selected from the group consisting of: (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methyl-1-propen-1-yl)-3-furanyl]-2-hexen-1-yl (3d); or a (substituted) polyenyl chain selected from the group consisting of: 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a);
[0274] R4 is: H; CH3, OH; OCH3; chlorine or 3,3-dimethylallyl chain (1h);
[0275] R5 is: H; a C5 isoprenoid chain selected from the group consisting of: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl (epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dihydroxy-3-methylbutyl) (1h), methylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); a C10 isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy- 3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl )(2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (nerolidol) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavenderyl) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadien-1-yl (2m), 3,7-dimethyl-5-oxo-2,6-octadien-1-yl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of: 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl) ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecanyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxodecanyl (10a), trialkyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains represented by the following: vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group may be cyclized with the adjacent OH group to form a methylenedioxy bridge; or a derivative or analog thereof. ;
[0276] In one embodiment, the first compound has the general formula I,
[0277]
[0278] in
[0279] R2 is hydrogen and R4 is not hydrogen;
[0280] or its derivatives or analogs.
[0281] In one embodiment, the first compound has the general formula I,
[0282]
[0283] in:
[0284] R2 is hydrogen and R5 is not hydrogen;
[0285] or its derivatives or analogs.
[0286] In one embodiment, the first compound has the general formula I,
[0287]
[0288] in:
[0289] R1 and R3 are each independently: OH; OCH3; O-glycoside; or sulfate;
[0290] R2 is: H; 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h); or (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h);
[0291] R4 is: H; and
[0292] R5 is pentyl; benzyl (6a); 2-phenylethyl (6b);
[0293] or phenylvinyl (14a), or a derivative or the like thereof.
[0294] In one embodiment, the first compound has the general formula I,
[0295]
[0296] in:
[0297] R1=OH; O-glycoside; or sulfate;
[0298] R2 is: H; [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e); 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g); (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h); (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i); or 5-methyl-2-(1-methylethyl)cyclohexyl (2o);
[0299] R3 is OH; OCH3; O-glycoside; or sulfate;
[0300] R4 is: H;
[0301] R5 is CH3; n-propyl, n-butyl or pentyl,
[0302] or its derivatives or analogs.
[0303] In one embodiment, the first compound of Formula I is cannabidiolic acid (CAS No. 1244-58-2) or a derivative or analog thereof.
[0304] In one embodiment, the first compound is CBDA, CBGA, CBNA, or a derivative or analog thereof.
[0305] In one embodiment, the first compound is CBGA, CBNA, or a derivative or analog thereof.
[0306] In one embodiment, the first compound is CBGA or a derivative or analog thereof.
[0307] In one embodiment, the first compound is CBNA or a derivative or analog thereof.
[0308] In one embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2) or a derivative or analog thereof as an AMP-activated protein kinase (AMPK) activator and a second compound of a sodium-glucose cotransporter-2 (SGLT2) inhibitor or a derivative or analog thereof.
[0309] In one embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as an AMP-activated protein kinase (AMPK) activator and a second compound selected from the group consisting of dapagliflozin, canagliflozin, empagliflozin, atagliflozin, repagliflozin, sergliflozin, phlorizin and their derivatives as a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0310] In one embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as an AMP-activated protein kinase (AMPK) activator and a second compound selected from the group consisting of dapagliflozin, canagliflozin, phlorizin and empagliflozin and their derivatives as a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0311] In one embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as an AMP-activated protein kinase (AMPK) activator and a second compound comprising at least one of the following as a sodium-glucose cotransporter-2 (SGLT2) inhibitor: dapagliflozin, canagliflozin, empagliflozin, atagliflozin, repagliflozin, sergliflozin, phlorizin and their derivatives.
[0312] In one embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as an AMP-activated protein kinase (AMPK) activator and a second compound comprising dapagliflozin or its derivatives as a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0313] In a preferred embodiment, the composition for activating AMPK comprises a first compound of cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as an AMP-activated protein kinase (AMPK) activator and a second compound comprising dapagliflozin or its derivatives or analogs as a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0314] The first compound (e.g., an AMPK activator, such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and the second compound (e.g., an SGLT2 inhibitor, such as dapagliflozin, phlorizin, or a derivative or analog thereof) of the composition for activating AMPK can be administered in any pharmaceutically effective amount according to the present invention. Generally, the pharmaceutically effective amount will depend on the type, age, body shape, health status, lifestyle and / or genetic inheritance of the subject. The pharmaceutically effective amount can be divided into several smaller amounts and administered throughout the day so that the total daily intake is an effective amount. Those skilled in the art will be able to recommend the consumption of an appropriate amount of the first compound (e.g., an AMPK activator, such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and the second compound (e.g., an SGLT2 inhibitor, such as dapagliflozin or a derivative or analog thereof) every day.
[0315] In one embodiment, the composition of the present invention can have an acute effect that can be observed in less than one month. Additionally or alternatively, the composition can have a long-term effect, and therefore various embodiments include applying the composition to an individual (e.g., oral) for a period of at least one month; preferably at least two months, more preferably at least three months, four months, five months, or six months; most preferably at least one year. During this period, the composition can be applied to an individual at least one day per week; preferably at least two days per week, more preferably at least three days, four days, five days, or six days per week; most preferably seven days per week. The composition can be applied every day with a single dose or every day with a variety of individual doses. In one embodiment, a single dose is not less than about 100mg. In one embodiment, a single dose is no more than about 1000mg. In one embodiment, a single dose is between about 100mg and about 1000mg.
[0316] In one embodiment, the first compound of the present invention (e.g., an AMPK activator, such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or a derivative or analog thereof) can be administered at a daily dose of between about 1 mg and about 10,000 mg, a daily dose of between 5 mg and about 5,000 mg, a daily dose of between about 10 mg and about 2,000 mg, a daily dose of between about 50 mg and about 1,500 mg, a daily dose of between about 100 mg and about 1,000 mg, or a daily dose of between about 100 mg and about 1,000 mg. The dosage is preferably provided in an amount of about 150 mg to about 900 mg, about 200 mg to about 800 mg, about 250 mg to about 750 mg, about 300 mg to about 700 mg, about 350 mg to about 650 mg, about 400 mg to about 600 mg, about 450 mg to about 550 mg, preferably about 500 mg.
[0317] In one embodiment, the second compound of the invention (e.g., an SGLT2 inhibitor such as dapagliflozin, phlorizin, or a derivative or analog thereof) is provided in an amount of between about 1 mg and about 2000 mg per day, between about 50 mg and about 1500 mg per day, or between about 100 mg and about 1000 mg per day.
[0318] In one embodiment, the second compound of the invention (e.g., an SGLT2 inhibitor such as dapagliflozin or a derivative or analog thereof) is administered at a daily dose of between about 1.1 mg and about 40 mg, between about 1.4 mg and about 38.8 mg, between about 1.7 mg and about 37.6 mg, between about 2.0 mg and about 36.4 mg, between about 2.3 mg and about 35.2 mg, between about 2.6 mg and about 34 mg. , between about 2.9 mg and about 32.8 mg per day, between about 3.2 mg and about 31.6 mg per day, between about 3.5 mg and about 30.4 mg per day, between about 3.8 mg and about 29.2 mg per day, between about 4.1 mg and about 28 mg per day, between about 4.4 mg and about 26.8 mg per day, between about 4.7 mg and about 25.6 mg per day, between about 5.0 mg and about 24.4 mg per day daily dose, between about 5.3 mg and about 23.2 mg daily dose, between about 5.8 mg and about 22 mg daily dose, between about 6.1 mg and about 20.8 mg daily dose, between about 6.4 mg and about 19.6 mg daily dose, between about 6.7 mg and about 18.4 mg daily dose, between about 7.0 mg and about 17.2 mg daily dose, between about 7.3 mg and about 16 mg daily dose, between about 7.6 mg and about 14.8 mg daily dose, between about 10.5 mg and about 15.9 mg daily dose, between about 12.5 mg and about 16.9 mg daily dose, between about 14.8 mg and about 18.4 mg daily dose, between about 15.5 mg and about 19.6 mg daily dose, between about 16.5 mg and about 18.4 mg daily dose, between about 17.0 mg and about 17.2 mg daily dose, between about 18.5 mg and about 19.6 mg daily dose, between about 18.5 mg and about 18.4 mg daily dose, between about 19. A daily dose of between about 7.9 mg and about 13.6 mg, a daily dose of between about 8.2 mg and about 12.4 mg, a daily dose of between about 8.5 mg and about 11.2 mg, a daily dose of between about 8.8 mg and about 6 mg, a daily dose of between about 9.1 mg and about 11.0 mg, a daily dose of between about 9.4 mg and about 10.8 mg, a daily dose of between about 9.7 mg and about 10.4 mg, preferably a daily dose of about 10 mg is provided.
[0319] In one embodiment, the composition for activating AMPK comprises a first compound (e.g., an AMPK activator, such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or their derivatives or analogs) in an amount of between about 100 mg and about 1000 mg per day, preferably about 500 mg per day, and a second compound (e.g., an SGLT2 inhibitor, such as dapagliflozin or its derivatives or analogs) in an amount of between about 1.1 mg and about 40 mg per day, preferably about 10 mg per day. In a preferred embodiment, the nutritional composition or nutritional supplement comprises a first compound (e.g., an AMPK activator, such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or their derivatives or analogs) in an amount of between about 100 mg and about 1000 mg per day, and a second compound (e.g., an SGLT2 inhibitor, such as dapagliflozin or its derivatives or analogs) in an amount of about 10 mg per day.
[0320] In another embodiment, the nutritional composition or nutritional supplement comprises a daily dosage amount of about 100 mg of the first compound (e.g., an AMPK activator such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a daily dosage amount of about 10 mg of the second compound (e.g., an SGLT2 inhibitor such as dapagliflozin or its derivatives or analogs).
[0321] In another embodiment, the nutritional composition or nutritional supplement comprises a daily dosage amount of about 200 mg of the first compound (e.g., an AMPK activator such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a daily dosage amount of about 10 mg of the second compound (e.g., an SGLT2 inhibitor such as dapagliflozin or its derivatives or analogs).
[0322] In another embodiment, the nutritional composition or nutritional supplement comprises a daily dosage amount of about 300 mg of the first compound (e.g., an AMPK activator such as cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a daily dosage amount of about 10 mg of the second compound (e.g., an SGLT2 inhibitor such as dapagliflozin or its derivatives or analogs).
[0323] In another embodiment, the nutritional composition or nutritional supplement comprises a daily dosage amount of about 400 mg of a first compound (e.g., an AMPK activator such as cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a daily dosage amount of about 10 mg of a second compound (e.g., an SGLT2 inhibitor such as dapagliflozin or a derivative or analog thereof).
[0324] In one embodiment, a composition comprising a first compound of cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs as AMP-activated protein kinase (AMPK) activators and a second compound comprising dapagliflozin or its derivatives as a sodium-glucose cotransporter-2 (SGLT2) inhibitor can be used as a nutritional composition or nutritional supplement. For example, a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs, or their derivatives or analogs) and a second compound (e.g., dapagliflozin or its derivatives) may be beneficial to a human subject (e.g., an elderly person or patient in need of improved metabolic health) to synergistically activate AMPK, thereby improving his / her metabolic health.
[0325] In one embodiment, a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin, or a derivative thereof) can be used for daily supplementation or routine administration. For example, a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a second compound (e.g., dapagliflozin or a derivative thereof) can be administered to an elderly person or patient who needs to improve metabolic health. In one embodiment, a composition comprising a first compound (e.g., cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin or a derivative thereof) can be administered to a human subject having a metabolic disorder such as obesity, type 2 diabetes, cardiovascular disease, or having an obesity-related condition such as diabetic complications, insulin sensitivity, polycystic ovary disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia.
[0326] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin, or a derivative thereof) may further comprise at least one of an excipient, a diluent, or a carrier. In one embodiment, the first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and the second compound (e.g., dapagliflozin or a derivative thereof) may be dissolved or suspended in a diluent or a carrier.
[0327] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may further comprise an excipient. Exemplary excipients may be excipients described in Handbook of Pharmaceutical Excipients, American Pharmaceutical Association (1986).
[0328] Non-limiting examples of suitable excipients may include buffers, preservatives, stabilizers, binders, compacting agents, lubricants, chelating agents, dispersion enhancers, disintegrants, flavoring agents, sweeteners, coloring agents.
[0329] In some embodiments, the excipient can be a buffer. The non-limiting example of a suitable buffer can include sodium citrate, magnesium carbonate, magnesium bicarbonate, calcium carbonate and calcium bicarbonate. Sodium bicarbonate, potassium bicarbonate, magnesium hydroxide, magnesium lactate, magnesium gluconate, aluminum hydroxide, sodium citrate, sodium tartrate, sodium acetate, sodium carbonate, sodium polyphosphate, potassium polyphosphate, sodium pyrophosphate, potassium pyrophosphate, disodium hydrogen phosphate, dipotassium hydrogen phosphate, trisodium phosphate, tripotassium phosphate, potassium metaphosphate, magnesium oxide, magnesium hydroxide, magnesium carbonate, magnesium silicate, calcium acetate, calcium glycerophosphate, calcium chloride, calcium hydroxide and other calcium salts or their combinations can be used as buffers in the pharmaceutical composition.
[0330] In some embodiments, the excipient may include a preservative. Non-limiting examples of suitable preservatives may include antioxidants such as alpha-tocopherol and ascorbate, and antimicrobial agents such as parabens, chlorobutanol and phenol. Antioxidants may also include, but are not limited to, EDTA, citric acid, ascorbic acid, butylated hydroxytoluene (BHT), butylated hydroxyanisole (BHA), sodium sulfite, p-aminobenzoic acid, glutathione, propyl gallate, cysteine, methionine, ethanol and N-acetylcysteine. In some cases, the preservative can include validamycin A, TL-3, sodium orthovanadate, sodium fluoride, Na-tosyl-Phe-chloromethyl ketone, Na-tosyl-Lys-chloromethyl ketone, aprotinin, phenylmethylsulfonyl fluoride, diisopropyl fluorophosphate, kinase inhibitors, phosphatase inhibitors, caspase inhibitors, granzyme inhibitors, cell adhesion inhibitors, cell division inhibitors, cell cycle inhibitors, lipid signaling inhibitors, protease inhibitors, reducing agents, alkylating agents, antibacterial agents, oxidase inhibitors or other inhibitors.
[0331] In one embodiment, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may also include a binder. Non-limiting examples of suitable binders may include starch, pregelatinized starch, gelatin, polyvinyl pyrrolidone, cellulose, methyl cellulose, sodium carboxymethyl cellulose, ethyl cellulose, polyacrylamide, polyvinyl oxazolidinone, polyvinyl alcohol, C12-C18 fatty acid alcohols, polyethylene glycol, polyols, sugars, oligosaccharides and combinations thereof.
[0332] In one embodiment, the binder can be selected from starches such as potato starch, corn starch, wheat starch; sugars such as sucrose, glucose, dextrose, lactose, maltodextrin; natural and synthetic gums; gelatin; cellulose derivatives such as microcrystalline cellulose, hydroxypropyl cellulose, hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, methyl cellulose, ethyl cellulose; polyvinyl pyrrolidone (povidone); polyethylene glycol (PEG); waxes; calcium carbonate; calcium phosphate; alcohols such as sorbitol, xylitol, mannitol, water or combinations thereof.
[0333] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may also include a lubricant as an excipient. Non-limiting examples of suitable lubricants may include magnesium stearate, calcium stearate, zinc stearate, hydrogenated vegetable oil, hydrogenated castor oil, polyoxyethylene monostearate, talc, polyethylene glycol, sodium benzoate, sodium lauryl sulfate, magnesium lauryl sulfate, and light mineral oil. The lubricant that can be used in the pharmaceutical composition can be selected from metal stearates (such as magnesium stearate, calcium stearate, aluminum stearate), fatty acid esters (such as sodium stearyl fumarate), fatty acids (such as stearic acid), fatty alcohols, glyceryl behenate, mineral oil, paraffin, hydrogenated vegetable oil, leucine, polyethylene glycol (PEG), metal lauryl sulfate (such as sodium lauryl sulfate, magnesium lauryl sulfate), sodium chloride, sodium benzoate, sodium acetate and talc, or a combination thereof.
[0334] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may also include a dispersion enhancer as an excipient. Non-limiting examples of suitable dispersants may include starch, alginic acid, polyvinyl pyrrolidone, guar gum, kaolin, bentonite, purified lignocellulose, sodium starch glycolate, isoamorphous silicate and microcrystalline cellulose as high HLB emulsifier surfactants.
[0335] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may also include a disintegrant as an excipient. In some embodiments, the disintegrant may be a non-effervescent disintegrant. Non-limiting examples of suitable non-effervescent disintegrants may include starches such as corn starch, potato starch, pregelatinized and modified starches thereof, sweeteners, clays such as bentonite, microcrystalline cellulose, alginates, sodium starch glycolate, gums such as agar, guar gum, locust bean gum, kana gum, pectin and tragacanth. In some embodiments, the disintegrant may be an effervescent disintegrant. Non-limiting examples of suitable effervescent disintegrants may include combinations of sodium bicarbonate and citric acid and combinations of sodium bicarbonate and tartaric acid.
[0336] In some embodiments, the excipient may include a flavoring agent. The flavoring agent incorporated into the outer layer may be selected from synthetic flavoring oils and flavoring aromatics; natural oils; extracts of plants, leaves, flowers and fruits; and combinations thereof. In some embodiments, the flavoring agent may be selected from the group consisting of: cinnamon oil; wintergreen oil; peppermint oil; clover oil; hay oil; anise oil; eucalyptus; vanilla; citrus oils such as lemon oil, orange oil, grape oil and grapefruit oil; and fruit essences including apple, peach, pear, strawberry, raspberry, cherry, plum, pineapple and apricot.
[0337] In some embodiments, the excipient may include a sweetener. Non-limiting examples of suitable sweeteners may include glucose (corn syrup), dextrose, invert sugar, fructose, and mixtures thereof (when not used as a carrier); saccharin and its various salts, such as sodium salt; dipeptide sweeteners, such as aspartame; dihydrochalcone compounds, glycyrrhizin; Stevia Rebaudiana (stevioside); chlorinated derivatives of sucrose, such as sucralose; and sugar alcohols, such as sorbitol, mannitol, xylitol, and the like.
[0338] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin, or a derivative thereof) may include a colorant. Non-limiting examples of suitable colorants may include food, drug, and cosmetic colors (FD&C), drug and cosmetic colors (D&C), and external drug and cosmetic colors (Ext. D&C). Colorants may be used as dyes or their corresponding lakes.
[0339] In some embodiments, a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin, or a derivative thereof) may include a diluent. Non-limiting examples of diluents may include water, glycerol, methanol, ethanol, and other similar biocompatible diluents. In some embodiments, the diluent may be an aqueous solution of an acid, such as acetic acid, citric acid, maleic acid, hydrochloric acid, phosphoric acid, nitric acid, sulfuric acid, or the like. In some embodiments, the diluent may be used to titrate the pH of the compound to a pH such as physiological pH to produce a salt as described above. In other cases, the diluent can be selected from the group consisting of alkaline metal carbonates such as calcium carbonate; alkaline metal phosphates such as calcium phosphate; alkaline metal sulfates such as calcium sulfate; cellulose derivatives such as cellulose, microcrystalline cellulose, cellulose acetate; magnesium oxide, dextrin, fructose, dextrose, palmitoyl stearin, lactitol, kaolin, lactose, maltose, mannitol, simethicone, sorbitol, starch, pregelatinized starch, talc, xylitol and / or anhydrous compounds, hydrates and / or their pharmaceutically acceptable derivatives or combinations thereof.
[0340] In some embodiments, the composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) may include a surfactant. The surfactant may be selected from, but not limited to, polyoxyethylene sorbitan fatty acid esters (polysorbates), sodium lauryl sulfate, sodium stearyl fumarate, polyoxyethylene alkyl ethers, sorbitan fatty acid esters, polyethylene glycol (PEG), polyoxyethylene castor oil derivatives, sodium docusate, quaternary ammonium compounds, amino acids such as L-leucine, fatty acid sugar esters, fatty acid glycerides, or combinations thereof.
[0341] The composition can be applied by any method understood by those skilled in the art.For example, the first compound of the present invention (for example, cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and the second compound (for example, dapagliflozin, phlorizin or its derivatives) or their compositions are preferably applied by oral administration.In some embodiments, the first compound of the present invention (for example, cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and the second compound (for example, dapagliflozin, phlorizin or its derivatives) or their compositions can be applied by the following methods: intravenous administration, topical administration, parenteral administration, intraperitoneal administration, intramuscular administration, intrathecal administration, intralesional administration, intracranial administration, intranasal administration, intraocular administration, intracardiac administration, intravitreal administration, intraosseous administration, intracerebral administration, intraarterial administration, intraarticular administration, intradermal administration, transdermal administration, transmucosal administration, sublingual administration, enteral administration, under the lip, insufflation administration, suppository administration, inhalation administration or subcutaneous administration.
[0342] In some embodiments, the composition of the present invention may have an acute effect that can be observed in less than one month. In addition or alternatively, the composition may have a long-term effect, and therefore various embodiments include administering the composition to an individual (e.g., orally) for a period of at least one month; preferably at least two months, more preferably at least three months, four months, five months, or six months; most preferably at least one year. During this period, the composition may be administered to an individual at least one day per week; preferably at least two days per week, more preferably at least three days, four days, five days, or six days per week; most preferably seven days per week. The composition may be administered daily in a single dose or daily in a variety of separate doses. In one embodiment, a single dose is not less than about 100 mg. In one embodiment, a single dose is no more than about 1000 mg. In one embodiment, a single dose is between about 100 mg and about 1000 mg.
[0343] In one embodiment, the composition comprising a first compound (e.g., cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or its derivatives) can be in liquid form or in solid form (e.g., solid dosage form).
[0344] In some embodiments, the solid dosage form of the composition for oral administration may include capsules, tablets, caplets, pills, lozenges, pastilles, powders and granules. In one embodiment, the first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and the second compound (e.g., dapagliflozin, phlorizin or its derivatives) of the composition are in two separate solid dosage forms.
[0345] In one embodiment, the first compound of the composition (e.g., cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and the second compound (e.g., dapagliflozin, phlorizin or its derivatives) are in the same solid dosage form.
[0346] For example, the capsule may include a core material and a shell wall encapsulating the core material, the core material including a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and / or a second compound (e.g., dapagliflozin, phlorizin or its derivatives). In some embodiments, the core material may include at least one of a solid, a liquid and an emulsion. In some embodiments, the shell wall material may include at least one of a soft gelatin, a hard gelatin and a polymer. Suitable polymers may include, but are not limited to, cellulosic polymers such as hydroxypropylcellulose, hydroxyethylcellulose, hydroxypropylmethylcellulose (HPMC), methylcellulose, ethylcellulose, cellulose acetate, cellulose acetate phthalate, cellulose acetate trimellitate, hydroxypropylmethylcellulose phthalate, hydroxypropylmethylcellulose succinate, and sodium carboxymethylcellulose; acrylic polymers and copolymers such as those formed from acrylic acid, methacrylic acid, methyl acrylate, ammonium methacrylate, ethyl acrylate, methyl methacrylate, and / or ethyl methacrylate (e.g., those copolymers sold under the trade name "Eudragit"); vinyl polymers and copolymers such as polyvinyl pyrrolidone, polyvinyl acetate, polyvinyl acetate phthalate, vinyl acetate crotonic acid copolymers, and ethylene-vinyl acetate copolymers; and shellac (purified shellac). In some embodiments, at least one polymer may be used as a taste masking agent.
[0347] In some embodiments, tablets, pills, etc. can be compressed, compressed multiple times, multilayered and / or coated. For example, the coating can be monolayer or multilayer. In some embodiments, the coating material (i.e., a composition comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and / or a second compound (e.g., dapagliflozin, phlorizin or its derivatives)) may include at least one of sugars, polysaccharides and glycoproteins extracted from at least one of plants, fungi and microorganisms. Non-limiting examples may include corn starch, wheat starch, potato starch, tapioca starch, cellulose, hemicellulose, glucan, maltodextrin, cyclodextrin, inulin, pectin, mannan, gum arabic, locust bean gum, mesquite gum, guar gum, karaya gum, ghatti gum, tragacanth gum, funori, carrageenan, agar, alginate, chitosan or gellan gum. In some embodiments, the coating material may include protein. In some embodiments, the coating material may include at least one of fat and / or oil. In some embodiments, the at least one of fat and / or oil may be high temperature molten. In some embodiments, the at least one of fat and / or oil may be hydrogenated or partially hydrogenated. In some embodiments, the at least one of fat and / or oil may be derived from plants. In some embodiments, the at least one of fat and / or oil may include at least one of glycerides, free fatty acids and fatty acid esters. In some embodiments, the coating material may include at least one edible wax. Edible wax may be derived from animals, insects or plants. Non-limiting examples may include beeswax, lanolin, bayberry wax, carnauba wax and rice bran wax. Tablets and pills may be prepared with enteric coatings in addition.
[0348] Liquid formulations of compositions comprising a first compound (e.g., cannabidiol acid (CAS No. 1244-58-2), CBGA, CBNA, or derivatives or analogs thereof) and / or a second compound (e.g., dapagliflozin, phlorizin, or derivatives thereof) may include syrups (e.g., oral formulations), intravenous formulations, intranasal formulations, ophthalmic formulations (e.g., for treating eye infections), otic formulations (e.g., for treating ear infections), ointments, creams, aerosols, and the like. In some cases, a combination of various formulations may be administered. In some embodiments, tablets, pills, and the like may be formulated for extended release profiles. In some embodiments, the composition may be formulated to increase shelf stability when stored in a closed container under standard ambient conditions.
[0349] Each component in the composition of the present invention can be used in any amount effective to achieve the purpose of the present invention (i.e., to increase the micronutrient level of the subject's breast milk after the subject gives birth). For example, a skilled person will be able to determine the appropriate dosage depending on the age, size and health of each specific subject, their lifestyle and their genetic inheritance.
[0350] In one embodiment, the amount used in the present application is the amount of a daily dose. Depending on the age, body shape and health status of each specific subject, its lifestyle and its genetic inheritance, the amount of each component can be used or changed (e.g., increased or decreased) according to the disclosed amount. In one embodiment, the nutritional composition or nutritional supplement of the present invention can be regularly applied, such as twice a day, every day, every two days or weekly.
[0351] In one aspect, the composition of the invention can be in any form suitable for administration of all ingredients. For example, the composition of the invention can be in the form of a powdered nutritional composition for reconstitution in milk or water, a food product, a beverage, a nutritional supplement or a nutraceutical.
[0352] When the composition of the present invention is in the form of a powdered nutritional composition to be reconstituted in milk or water, the nutritional composition or nutritional supplement may preferably include a protein source, a carbohydrate source and a lipid source, preferably together with lecithin. The composition may also include soy lecithin and / or a leavening agent. The protein source may be milk powder or skim milk powder. Sucrose and / or maltodextrin may be used as a carbohydrate source. The lipid source may be a vegetable oil. Alternatively or in addition thereto, the preparation may also include glucose syrup, milk fat, magnesium citrate, choline salts and choline esters, prebiotic fiber and / or ascorbyl palmitate. For example, flavor compounds (e.g., cocoa powder or honey) may be added to provide different tastes.
[0353] In another aspect, the composition of the present invention may be a product selected from the group consisting of a nutritional product, a functional food product, a healthy aging product, a dairy product, a dairy substitute product, a beverage product, a dietary product and a pet food product.
[0354] In one embodiment, a composition comprising a first compound (e.g., cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or a derivative or analog thereof) and a second compound (e.g., dapagliflozin, phlorizin or a derivative thereof) can be used to treat or prevent a condition, disorder or disease associated with type 2 diabetes, non-alcoholic fatty liver disease and / or obesity in a subject.
[0355] In one embodiment, the condition can be a metabolic disorder such as obesity, type 2 diabetes, cardiovascular disease or obesity-related disorders such as diabetic complications, insulin sensitivity, polycystic ovary disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia.
[0356] In another embodiment, a composition comprising a first compound (e.g., cannabidiolic acid (CAS No. 1244-58-2), CBGA, CBNA or their derivatives or analogs) and a second compound (e.g., dapagliflozin, phlorizin or their derivatives) can be used to treat or prevent a condition selected from the group consisting of obesity, type 2 diabetes, cardiovascular disease, diabetic complications, insulin sensitivity, polycystic ovary disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia.
[0357] method
[0358] Another aspect of the present disclosure is a method for improving metabolic health (e.g., treating or preventing metabolic disorders or obesity-related conditions) by synergistically activating AMPK. In one embodiment, the method comprises administering to a subject in need thereof a composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
[0359] In one embodiment, the method for improving metabolic health includes treating or preventing a metabolic disorder. In one embodiment, the metabolic disorder includes obesity, type 2 diabetes, cardiovascular disease. In one embodiment, the metabolic disorder is selected from the group consisting of obesity, type 2 diabetes, and cardiovascular disease.
[0360] In another embodiment, the method for improving metabolic health includes treating or preventing obesity-related conditions. In one embodiment, obesity-related conditions include diabetic complications, insulin sensitivity, polycystic ovarian disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia. In one embodiment, obesity-related conditions are selected from the group consisting of: diabetic complications, insulin sensitivity, polycystic ovarian disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia.
[0361] In one embodiment, the present disclosure is a method of treating or preventing a condition selected from the group consisting of obesity, type 2 diabetes, cardiovascular disease, diabetic complications, insulin sensitivity, polycystic ovary disease, hyperglycemia, dyslipidemia, insulin resistance, metabolic syndrome, obesity, weight gain, inflammatory diseases, digestive organ diseases, angina pectoris, myocardial infarction, sequelae of angina pectoris or myocardial infarction, senile dementia and cerebrovascular dementia.
[0362] In another embodiment, the disclosure is a method of treating or preventing a condition, disorder or disease associated with type 2 diabetes, non-alcoholic fatty liver disease and / or obesity in a subject by activating AMPK.
[0363] As disclosed above, the method comprises administering to a subject in need thereof a composition comprising a combination of an AMP-activated protein kinase (AMPK) activator (e.g., CBDA) and a sodium-glucose cotransporter-2 (SGLT2) inhibitor to activate AMPK.
[0364] In one embodiment, the first compound of Formula I is cannabidiolic acid, CAS No. 1244-58-2, and the second compound is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin, phlorizin and erpagliflozin.
[0365] In one embodiment, the first compound is CBDA, CBGA or CBNA, and the second compound is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin, phlorizin and erpagliflozin.
[0366] In one embodiment, the second compound is selected from the group consisting of empagliflozin, canagliflozin and dapagliflozin.
[0367] In one embodiment, the second compound comprises dapagliflozin.
[0368] In one embodiment, the second compound is dapagliflozin.
[0369] In one embodiment, the second compound is phlorizin.
[0370] In one embodiment, the first compound is CBDA, CBGA or CBNA and the second compound is phlorizin.
[0371] In one embodiment, the first compound of Formula I is cannabidiolic acid, CAS No. 1244-58-2, and the second compound is dapagliflozin.
[0372] In one embodiment, the method comprises administering to a subject in need thereof a composition comprising a combination of a first compound of cannabidiolic acid (CAS No. 1244-58-2) and a second compound of dapagliflozin to activate AMPK.
[0373] In one embodiment, activation of AMPK is via a direct activation mechanism or an indirect activation mechanism.
[0374] In one embodiment, activation of AMPK is via a direct activation mechanism.
[0375] In one embodiment, activation of AMPK occurs at any tissue of a subject associated with a condition, disorder, or disease.
[0376] In one embodiment, the activation of AMPK is in muscle, liver and / or kidney tissue.
[0377] In one embodiment, the activation of AMPK is where activated AMPK comprises an α2 subunit, a β1 subunit, and a γ1 subunit.
[0378] In one embodiment, the first compound is obtained from a plant or a plant extract.
[0379] As shown in Example 1 and Figure 1, a composition comprising about 1 μM or about 0.5 μM of CBD or CBDA and about 1 μM of Dapa is administered to a subject. Example 1, Figure 1A It was shown that the combination of CBD and Dapa improved glucose clearance in zebrafish compared to CBD and Dapa (SGLT-2 inhibitor) alone. Figure 1B It was shown that the combination of CBDA and Dapa improved glucose clearance in zebrafish compared to CBDA and Dapa (SGLT-2 inhibitor) alone.
[0380] In one embodiment, the composition of the invention can cause at least 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23% improvement in glucose clearance in a subject compared to a control subject not administered a composition comprising a first compound of CBD or CBDA or a second compound of Dapa of the invention, or compared to a control subject administered a composition comprising a first compound of CBD or CBDA or a second compound of Dapa. , 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, 35%, 36%, 37%, 38%, 39%, 40%, 41%, 42%, 43%, 44%, 45%, 46%, 47%, 48%, 49%, 50%, 51%, 52%, 53%, 54%, 55%, 56%, 57%, 58%, 59%, 60%, 61%, 62%, 63%, 64%, 65%, 66%, 67%, 68%, 69%, 70%, 71%, 72%, 73%, 74%, 75%, 76%, 77%, 78%, 79%, 80% increase.
[0381] In one embodiment, the increase in glucose clearance may persist for up to 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, 13 months, 14 months, 15 months, 16 months, 17 months, 18 months, 19 months, 20 months, 21 months, 22 months, 23 months, 24 months, 36 months, or 48 months.
[0382] Example
[0383] Example 1.
[0384] Figure 1 Figure 1A and Figure 1B ) is a set of graphs showing glucose clearance in zebrafish according to certain embodiments of the present invention. Figure 1A It was shown that the combination of CBD and Dapa improved glucose clearance in zebrafish compared to CBD and Dapa (SGLT-2 inhibitor) alone. Figure 1B It was shown that the combination of CBDA and Dapa improved glucose clearance in zebrafish compared to CBDA and Dapa (SGLT-2 inhibitor) alone.
Claims
1. A composition for activating AMPK, comprising: a first compound; and a second compound; Wherein the first compound has the general formula I, wherein R1 and R3 are each independently OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C20 alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 Polyalkynyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogues; or The first compound is cannabigerolic acid (CBGA) or cannabinolic acid (CBNA); wherein the second compound is a sodium-glucose cotransporter-2 (SGLT2) inhibitor.
2. The composition according to claim 1, wherein the sodium-glucose co-transporter-2 (SGLT2) inhibitor is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin, ertugliflozin, phlorizin and mixtures thereof.
3. The composition according to claim 1, wherein the sodium-glucose cotransporter-2 (SGLT2) inhibitor is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin and mixtures thereof.
4. The composition of claim 1, wherein the sodium-glucose cotransporter-2 (SGLT2) inhibitor comprises dapagliflozin.
5. The composition according to claim 1, wherein the sodium-glucose cotransporter-2 (SGLT2) inhibitor is dapagliflozin.
6. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; or sulfated O-glycoside; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 10 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; or sulfonate; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 Polyalkynyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
7. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; or acylated O-glycoside; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C 10 To C 20 optionally substituted and / or optionally branched C 10 To C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C20 polyalkynyl; R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; or nitro; optionally branched C1 to C 20 Alkyl; optionally branched C2 to C 20 Alkenyl; optionally branched C4 to C 20 Polyalkenyl; optionally branched C2 to C 20 Alkynyl, or an optionally branched C4 to C 20 Polyalkynyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
8. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; or acylated O-glycoside; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 polyalkyne; R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; or ester; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 Alkenyl; optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally substituted and / or optionally branched C2 to C 20 alkynyl, or an optionally substituted and / or optionally branched C4 to C 20 Polyalkynyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
9. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate; R2 is CH3, OH; O-glycoside; C-glycoside; sulfated O-glycoside; sulfated C-glycoside dichloride; CHO (aldehyde); sulfate; optionally substituted and / or optionally branched C2 to C 15 or optionally substituted and / or optionally branched C4 to C 15 Polyene; R4 is H; CH3, OH; OCH3; chlorine or 3,3-dimethylallyl chain (1h); R5 is H; optionally substituted and / or optionally branched C1 to C 20 Alkyl; optionally substituted and / or optionally branched C2 to C 20 or optionally substituted and / or optionally branched C4 to C 20 Polyalkenyl; optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
10. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; a C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl ( 1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 An isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 ,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (21), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methyl-1-propen-1-yl)-3-furanyl]-2-hexen-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5.j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e ), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (10b), 2 -(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecen-1-yl (13a), 2-phenylethylene 1-hydroxymethylene-2-oxopropyl (15a); or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; primary, secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3- Methylbutyl (1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (10), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a substituted alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyranan-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a); R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; secondary or tertiary amine; primary or secondary amide; cyano; nitro; sulfonate; sulfate; a C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl ( 1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 ,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (21), 3,7-dimethyl-7-hydroxy-2,5-octadien-1-yl (2m), 3,7-dimethyl-5-oxo-2,6-octadien-1 (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a substituted polyalkenyl chain selected from the group consisting of: 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group is capable of cyclizing with an adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
11. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate; R2 is OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl Butyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 An isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 ,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadien-1-yl (2m), 3,7-dimethyl-5-oxo-2,6-octadien-1 (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 An isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a substituted alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) , 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); a substituted alkenyl chain selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a); R4 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; Cl, I or F halogen atom; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl -2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); C 10 An isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (21), 3,7-dimethyl-7-hydroxy-2,5-octadien-1-yl (2m), 3,7-dimethyl-5-oxo-2,6-octadien-1-yl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e) ), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl ( 6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl ( 10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of: 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadien-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadien-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a); R5 is H; OH; OCH3; O-glycoside; C-glycoside; acylated O-glycoside; acylated C-glycoside; sulfated O-glycoside; sulfated C-glycoside; halogen; primary, secondary or tertiary alcohol; ketone; aldehyde; ester; sulfate; C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl butyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); 10 an isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)-3 , 7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of: 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8 -hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5 n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl)ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a) , 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxotridecyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); substituted alkenyl chains selected from the group consisting of vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a); or a substituted polyalkenyl chain selected from the group consisting of: 8, 11-heptadecen ... carbodiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group can be cyclized with the adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
12. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-aliphatic saturated or unsaturated acyl, O-glycoside; acylated O-glycoside; sulfated O-glycoside; or sulfate; R2 is CH3, OH; O-glycoside; C-glycoside; sulfated O-glycoside; sulfated C-glycoside dichloride; CHO (aldehyde); sulfate; C5 isoprenoid chain selected from the group consisting of: 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h), 1,1-dimethyl-2-propen-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-buten-1-yl (1j), 4-hydroxy-3-methyl-2-buten-1-yl (1k), 1-hydroxy-3-methyl-2-buten-1-yl (11), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); A C10 isoprenoid chain selected from the group consisting of 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2E)-3,7-dimethyl-2,6-octadien-1-yl ( geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (nerolidol) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavenderyl) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (2l), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 an isoprenoid chain selected from the group consisting of: (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methyl-1-propen-1-yl)-3-furanyl]-2-hexen-1-yl (3d); or a (substituted) polyenyl chain selected from the group consisting of: 8-(3,4-dihydroxyphenyl)-4,7-octadien-1-yl (18a); R4 is H; CH3, OH; OCH3 dichloro or 3,3-dimethylallyl chain (1h); R5 is H; a C5 isoprenoid chain selected from the group consisting of 3-methylbutyl (1a), 4-hydroxy-3-methylbutyl (1b), 3-hydroxy-3-methylbutyl (1c), 2-hydroxy-3-methylbutyl (1d), (3,3-dimethyl-2-oxiranyl)methyl(epoxyisoprenyl) (1e), 2,3-dihydroxy-3-methylbutyl (1f), 3-methyl-2-oxobutyl (1g), 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h) , 1,1-dimethyl-2-propene-1-yl (1,1-dimethylallyl) (1i), 3-methyl-1-butene-1-yl (1j), 4-hydroxy-3-methyl-2-butene-1-yl (1k), 1-hydroxy-3-methyl-2-butene-1-yl (1l), 3-hydroxy-3-methyl-1-butenyl (1m), 4-hydroxy-3-methylbut-1-en-1-yl (1n), 2-hydroxy-3-methyl-3-buten-1-yl (1o), 3-methyl-1,3-butadienyl (1p); A C10 isoprenoid chain selected from the group consisting of 3,7-dimethyloctyl (tetrahydrogeranyl) (2a), 8-hydroxy-3,7-dimethyloctyl (2b), 3,7-dimethyloct-6-en-1-yl (citronellyl) (2c), 6,7-dihydroxy-3,7-dimethyl-oct-2-enyl (2d), [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e), 5-hydroxy-5-methyl-2-(1-methylvinyl)hexyl (2f), 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g), (2e)- 3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h), (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i), 5-methyl-2-(1-methylvinyl)-4-hexen-1-yl (lavender) (2j), 5-hydroxy-3,7-dimethyl-2,6-octadien-1-yl (2k), 6-hydroxy-3,7-dimethyl-2,7-octadien-1-yl (21), 3,7-dimethyl-7-hydroxy-2,5-octadienyl (2m), 3,7-dimethyl-5-oxo-2,6-octadienyl (2n), 5-methyl-2-(1-methylethyl)cyclohexyl (2o); C 15 An isoprenoid chain selected from the group consisting of 3,7,11-trimethyldodecyl (hexahydrofarnesyl) (3a), (2E,6E)-3,7,11-trimethyl-2,6,10-dodecatrien-1-yl (farnesyl) (3b), 7-hydroxy-3,7,11-trimethyl-2,10-dodecadien-1-yl (3c), 3-methyl-6-[5-(2-methylprop-1-en-1-yl)furan-3-yl]hex-2-en-1-yl (3d); C 20 an isoprenoid chain selected from the group consisting of: 3,7,11,15-tetramethylhexadecyl (phytanyl) (4a), (2E,6E,10E)-3,7,11,15-tetramethylhexadecyl-2,6,10,14-tetraen-1-yl (geranylgeranyl) (4b); a (substituted) alkyl chain selected from the group consisting of: methyl, ethyl, propyl, butyl, pentyl, heptyl, nonyl, undecyl, pentadecyl, heptadecyl, eicosyl, hydroxymethyl (5a), 6-hydroxyheptyl (5b), 8-hydroxynonyl (5c), 12-hydroxytridecyl (5d), 2-hydroxytridecyl (5e), e), 2,12-dihydroxytridecyl (5f), 2-hydroxypentadecyl (5g), 14-hydroxypentadecyl (5h), 16-hydroxyheptadecyl (5i), 10-methoxyundecyl (5j), 12-methoxytridecyl (5k), 2-(acetoxy)pentadecyl (5l), 2-(acetoxy)-13-hydroxytridecyl (5m), 2-(acetoxy)-12-hydroxytridecyl (5n), 2,12-bis(acetoxy)tridecyl (5o), 2-(acetoxy)tridecyl (5p), benzyl (6a), 2-phenylethyl (6b), 2-(4-hydroxyphenyl) ethyl (6c), 2-(3,4-dihydroxyphenyl)ethyl (6d), 2-(4-methoxyphenyl)ethyl (6e), 2-hydroxy-2-phenylethyl (7a), 2-hydroxy-2-(2-hydroxyphenyl)ethyl (7b), tetrahydro-6-methyl-2H-pyran-2-yl)methyl (8a), 1,2-dioxopropyl (9a), 3-oxopentyl (9b), 2-oxopentyl (9c), 2-oxoheptyl (9d), 2-oxononyl (9e), 14-oxopentadecyl (9f), 2-oxotridecanyl (9g), 1-hydroxy-2-oxopropyl (10a), 13-hydroxy-2-oxodecanyl (10a), trialkyl (10b), 2-(4-hydroxyphenyl)-2-oxoethyl (11a), 2-oxo-2-phenylethyl (11b); (substituted) alkenyl chains represented by the following: vinyl (12a), 1-propenyl (12b), 1-methylvinyl (12c), 1-methyl-1-propen-1-yl (12d), 8-pentadecen-1-yl (12e), 8-heptadecen-1-yl (12f), 10-heptadecen-1-yl (12g), 10-(acetoxy)-8-pentadecenyl (13a), 2-phenylvinyl (14a), 1-hydroxymethylene-2-oxopropyl (15a);or a (substituted) polyalkenyl chain selected from the group consisting of: 8,11-heptadecadiene-1-yl (16a), 1-oxo-2,4-octadiene-1-yl (17a), 4,6-dihydroxy-6-methyl-3-oxo-1,4-cyclohexadiene-1-yl (17b), (6-methyl-4-oxo-4H-pyran-2-yl)methyl (17c), 8-(3,4-dihydroxyphenyl)-4,7-octadiene-1-yl (18a); optionally, the OCH3 group is capable of cyclization with an adjacent OH group to form a methylenedioxy bridge; or its derivatives or analogs.
13. The composition according to claims 6 to 12, wherein the first compound has the general formula I, in R2 is hydrogen and R4 is not hydrogen.
14. The composition according to claims 6 to 12, wherein the first compound has the general formula I, in: R2 is hydrogen and R5 is not hydrogen; or its derivatives or analogs.
15. The composition of claim 1, wherein the first compound has the general formula I, in: R1 and R3 are each independently: OH; OCH3; O-glycoside; or sulfate; R2 is H; 3-methyl-2-buten-1-yl (3,3-dimethylallyl) (1h); or (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h); R4 is H; and R5 is pentyl; benzyl (6a); 2-phenylethyl (6b); or phenylvinyl (14a), or its derivatives or analogs.
16. The composition of claim 15, wherein the first compound has the general formula I, in: R1=OH; O-glycoside; or sulfate; R2 is: H; [3-methyl-3-(4-methyl-3-penten-1-yl)-2-oxiranyl]methyl (geranyl 2,3-epoxide) (2e); 3-methyl-6-(1-methylvinyl)-2-cyclohexen-1-yl (2g); (2E)-3,7-dimethyl-2,6-octadien-1-yl (geranyl) (2h); (2Z)-3,7-dimethyl-2,6-octadien-1-yl (neryl) (2i); or 5-methyl-2-(1-methylethyl)cyclohexyl (2o); R3 is OH; OCH3; O-glycoside; or sulfate; R4 is: H; R5 is CH3; n-propyl, n-butyl or pentyl, or its derivatives or analogs.
17. A composition according to any one of claims 1 to 16, wherein the first compound of formula I is cannabidiolic acid, CAS No. 1244-58-2.
18. A composition according to any one of claims 1 to 17 for use in treating or preventing a condition, disorder or disease associated with type 2 diabetes, non-alcoholic fatty liver disease and / or obesity in a subject.
19. The composition according to any one of claims 1 to 18, wherein the activation of AMPK is via a direct activation mechanism.
20. The composition of any one of claims 1 to 18, wherein the activation of AMPK is in muscle, liver and / or kidney tissue.
21. The composition according to any one of claims 1 to 18, wherein the activation of AMPK is AMPK comprising an α2 subunit, a β1 subunit, and a γ1 subunit.
22. The composition according to any one of claims 1 to 21, wherein the first compound is obtained from a plant or a plant extract.
23. A composition according to any one of claims 1 to 22 for use in the preparation of a medicament for the treatment or prevention of a condition, disorder or disease responsive to AMPK activation.
24. The composition according to any one of claims 1 to 23, for use in activating AMPK.
25. The composition of any one of claims 1 to 24, wherein the composition is a food, a beverage or a dietary supplement.
26. The composition of any one of claims 1 to 24, wherein the composition further comprises a pharmaceutically acceptable carrier.
27. A composition according to any one of claims 24 to 26, wherein the compound of general formula I is compound 1; cannabidiol acid, CAS No. 1244-58-2.
28. The composition according to any one of claims 1 to 27, wherein the composition is a pharmaceutical composition for activating AMPK, comprising as an active ingredient a therapeutically effective amount of the first compound of formula I or a pharmaceutically acceptable salt or solvate thereof, a therapeutically effective amount of the second compound and a pharmaceutically acceptable carrier.
29. An in vitro method of activating AMPK, the method comprising contacting the composition according to any one of claims 1 to 28 with AMPK.
30. A method of treating or preventing a condition, disorder or disease associated with type 2 diabetes, non-alcoholic fatty liver disease and / or obesity, the method comprising administering a composition according to any one of claims 1 to 28.
31. The method of claim 30, wherein the first compound of formula I is cannabidiol acid, CAS No. 1244-58-2, CBGA or CBNA, and the second compound is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin, erpagliflozin, phlorizin and mixtures thereof.
32. The method of claim 31, wherein the second compound is selected from the group consisting of empagliflozin, canagliflozin, dapagliflozin, and mixtures thereof.
33. The method of claim 31, wherein the second compound comprises dapagliflozin.
34. The method of claim 31, wherein the second compound is dapagliflozin.
35. The method of claim 30, wherein the first compound of Formula I is cannabidiol acid, CAS No. 1244-58-2, and the second compound is dapagliflozin.
